Skip to main content
PLOS One logoLink to PLOS One
. 2026 Apr 16;21(4):e0333752. doi: 10.1371/journal.pone.0333752

Parental, pregnancy and neonatal characteristics during the perinatal period as potential risk factors for childhood cancer: FeToxCancer case-control study

Anja Stajnko 1, Jesse Daniel Thacher 1, Anna Oudin 2, Christian Lindh 1, Thomas Lundh 1, Ingrid Øra 3,4, Jenny Selander 5, Lars Rylander 1, Maria Albin 5, Karin Källén 1, Karin Broberg 1,5,*
Editor: Melvin Marzan6
PMCID: PMC13086354  PMID: 41990000

Abstract

Childhood cancer aetiology is poorly understood and is considered to originate in utero and early postnatal life. In this study, we investigated perinatal characteristics as potential risk factors by performing a population-based case-control study, including 1340 cancer cases diagnosed < 19y and born between 1989–2021 in southern Sweden, and 13400 controls matched by sex, year, and municipality of birth. Perinatal characteristics were obtained from seven national registries. Cox regression was used to examine the associations between perinatal characteristics and the risk of overall childhood cancer, leukaemia, CNS tumours, lymphoma, and other cancer types combined (OCT). Large for gestational age was associated with a higher risk of overall cancer (HR, 95%CI: 1.32, 1.02–1.69) and leukaemia (HR, 95%CI: 1.58, 1.01–2.5), while a 5-min Apgar score <7 indicated a higher risk of OCT (HR, 95%CI: 2.16, 1.12–4.15). Mechanical ventilation during neonatal care was associated with a higher risk of overall cancer (HR, 95%CI: 1.88, 1.39–2.53) and OCT (HR, 95%CI: 2.09, 1.19–3.39). The aforementioned characteristics were associated with up to a threefold increased risk among children diagnosed before six months of age compared to those diagnosed later. Additionally, maternal obesity was associated with a higher risk of CNS tumours (HR, 95%CI: 1.51, 1.04–2.21) and lymphoma (HR, 95%CI: 2.26, 1.31–3.88), and maternal underweight with a higher risk of leukaemia (HR, 95%CI: 2.43, 1.40–4.22). Planned caesarean delivery indicated an increased risk of OCT (HR, 95%CI: 1.52, 1.04–2.22). Our findings identify several perinatal characteristics associated with childhood cancer risk, highlighting the perinatal period as an important window for future etiological research.

Introduction

Cancer in early and late childhood is a rare condition and one of the leading causes of mortality among children in high-income countries. The Swedish Children’s Cancer Registry reported an average of 330 incident childhood cancer cases annually over the past decade [1], and around 400,000 annual incident cases are estimated worldwide [2]. While global childhood cancer incidence is increasing [3], Sweden`s rate has remained constant over the past decade [1]. The most frequently occurring childhood cancer types are leukaemia, brain and other central nervous system (CNS) tumours, lymphoma, and Wilms tumour [1,2]. Contrary to cancer in adults, the causes of childhood cancers are largely unknown. Investigations of the underlying genetic background have shown that, on average, only 7–10% of childhood cancer cases are carriers of germline mutations in cancer-predisposing genes [4–6]. Most childhood cancer cases likely result from de novo mutations in genes leading to uncontrolled cell growth and cancer. Given that approximately half of the childhood cancer diagnoses occur before the age of five, [1,7] the initial genetic mutations likely originate in utero and in early postnatal life [8,9]. Accordingly, multiple epidemiological studies have investigated several perinatal factors, including demographic, environmental, and intrinsic factors, as risk factors for childhood cancer [10–13]. Among these, more established risk factors are exposure to high-dose ionising radiation, prior chemotherapy, age, sex, and ethnicity (i.e., attributable to both genetic and environmental factors) [4,13]. Nevertheless, the list of perinatal characteristics as potential risk factors is growing. To name a few: maternal smoking, maternal BMI and age, birth weight and size, Apgar score, neonatal treatment, preterm birth, caesarean birth, and parental occupational exposure to chemicals [11,14–19]. However, evidence for most of these remains inconsistent and inconclusive [4,10]. Therefore, additional studies on perinatal factors are crucial to identify those with the highest risk for childhood cancer development.

We aimed to investigate associations between multiple parental, pregnancy, and neonatal characteristics during the perinatal period and the risk of overall childhood cancer, as well as specific cancer groups (i.e., leukaemia, CNS tumour, lymphoma, and other cancer types combined).

Materials and methods

Study design and population

This study is a part of the ongoing FeToxCancer project focusing on children born in Southern Sweden. Its main objective is to understand the effects of chemical exposure in utero and possible underlying mechanisms in the aetiology of childhood cancer. The study uses a population-based case-control design, comprising in Phase I extensive registry data (described here) and in Phase II measurements of inorganic and organic toxicants in biobanked maternal serum samples collected during infection screening in early pregnancy (2–14 weeks; presented in a separate paper) (Fig 1).

Fig 1. Flow chart of the FeToxCancer study design.

Fig 1

(in grey: phase II is ongoing and therefore not a part of this study; the map was produced using R programme (version 4.2.3) with Swedish county boundaries obtained from Eurostat’s GISCO database [23]).

Serum samples have been stored only within Southern Sweden (i.e., municipalities Skåne, Blekinge and Kronoberg) and are biobanked within the Southern Sweden Maternal Biobank since 1989; thus, this determined the time period and geographic location for the study population.

The FeToxCancer project was approved by the Swedish Ethical Review Authority (No. 2021–02001 and 2021–04399). The need for written consent from the participants was waived by the ethics committee.

Every Swedish resident is assigned a unique personal identification number (i.e., PIN). A valid PIN, expected for nearly 100% of mothers [20], was the primary inclusion criterion and enabled the cross-linkage of various population and health-related national registries (Fig 1). Firstly, all childhood cancer cases with the first diagnosis at age < 19 years and born between 1.1.1989–31.12.2021 (i.e., recruitment period) were selected from the National Cancer Register (NCR). The NCR was established in 1958, and documents cancer cases identified either clinically, by imaging, or by pathology examination, and has 96% coverage [21]. Secondly, cases were linked with the National Medical Birth Register (MBR), which was established in 1973 and contains high-quality pregnancy-related information for around 98% of deliveries in Sweden [22]. All childhood cancer cases born in the municipalities of Skåne (n = 1038), Blekinge (n = 157), and Kronoberg (n = 145) constituted our final case population (n = 1340; Fig 1). Cancer cases were classified into specific groups according to the International Classification of Childhood Cancer (ICCC, 3rd edition; https://seer.cancer.gov/iccc/iccc-iarc-2017.html).

For each case, ten controls matched by sex, birth year, and municipality of birth, were randomly selected from the MBR (n = 13400; Fig 1) from the same population. The inclusion criteria were being born between 1989 and 2021 with no known cancer diagnosis or recorded death before the age of 19, emigration or end of the study, while allowing for cancer diagnosis at the age of 19 or older.

Finally, various national registries were cross-linked (Fig 1) via the maternal PIN to obtain extensive data covering parental, child, and pregnancy characteristics.

The data (including information with the possibility to identify individual participants) was accessed for research purposes on 21st of March 2023.

Perinatal characteristics

The perinatal characteristics were selected based on current evidence in the literature [11,14–19] and the availability of data within the FeToxCancer study (Table 1). Investigated perinatal characteristics included: I) parental characteristics including cancer diagnosis of the mother (yes, no), maternal and paternal age at delivery (<25, 25–34 and ≥35 years), maternal and paternal education (primary, secondary, and postsecondary), birth order (i.e., parity; 1st, 2nd, and ≥3rd), maternal BMI (kg/m2) (<18.5 as underweight, 18.5–24.9 as normal, 25–29.9 as overweight, and ≥30 as obese), maternal smoking during the first trimester (yes, no), II) pregnancy characteristics including assisted pregnancy with in vitro fertilisation (IVF; yes, no) and mode of delivery (vaginal, planned caesarean, emergency caesarean, vaginal with forceps or vacuum); and III) neonatal characteristics including gestational age (<37 weeks as pre-term, 37–41 weeks as at term, and ≥42 weeks as post-term), birthweight according to the gestational age (adequate for gestational age (AGA), small for gestational age (SGA) or large for gestational age (LGA), Apgar score at five minutes of age (i.e., 5-min Apgar; ≥7 as reassuring, <7 as low), any childhood infection requiring specialist in-patient care from birth until the age of one year (yes, no), and admission to the neonatal intensive unit (yes, no).

Table 1. National registries used to obtain data for the investigated perinatal characteristics.

Registry Investigated perinatal characteristic: Data availability period
National Medical Birth Register Maternal Age 1989-2021
Parity (i.e., birth order) 1989-2021
Maternal BMIa 1989-2021
Gestational age (GA) 1989-2021
Birthweight (to calculate birthweight for GA) 1989-2021
Child`s sex (to calculate birthweight for GA) 1989-2021
Maternal smoking in the first trimester 1989-2021
[Maternal smoking in gestational week 30-32] [1990-2021]
Mode of delivery 1989-2021
Assisted pregnancy with IVF 1989-2006
5-min Apgar 1989-2021
[Gestational diabetes] [1997-2021]
Longitudinal Integrated Database for Health Insurance and Labour Market Studies (LISA) Paternal birthdate (to estimated paternal age) 1990-2020
Maternal education 1990-2020
Paternal education 1990-2020
[Parents’ birth country and nationality] [1990-2020]
The National Quality Register of Assisted Reproduction (Q-IVF) Assisted pregnancy with IVF 2007-2021
National Patient Register (in-patient care) Child infections
[Child cancer predisposing syndromeb]
1990-2021
[1990-2021]
[Maternal infection during pregnancy] [1990-2021]
Perinatal Revision South Register Neonatal care
[Mechanical ventilation and steroid treatment]
1995-2015
[1995-2015]
Swedish Neonatal Quality Register (SNQ) Neonatal care
[Mechanical ventilation, steroid treatment, phototherapy, antibiotic therapy, surfactant treatment]
2002-2021
[2002-2021]
National Cancer registry Maternal cancer 1989-2021

IVF – in vitro fertilisation, BMI – body mass index.

aat enrolment into the maternal health care.

bfor Down syndrome, Neurofibromatosis type 1, Congenital malformation syndromes involving early overgrowth (Beckwith-Wiedemann syndrome), and Von Hippel-Lindau syndrome.

in [ ] are additionally tested perinatal characteristics, which were not included in the main statistical analyses.

Parental education represents the highest recorded education based on the available data from 1990 to 2020. Maternal BMI was calculated based on maternal weight and height provided at the first antenatal visit in gestational weeks eight to ten. Gestational age (GA) was determined based on the ultrasound, as a superior measure, and in case of a missing ultrasound, based on the day of the last menstrual period (mostly before 1994). We investigated birthweight for GA rather than birth weight, since it has been previously reported as a superior predictor of childhood cancer risk [24]. Birthweight for GA was estimated based on the combination of gestational age, birth weight, and sex of the child and calculated according to the Swedish reference standard growth curves [25]. It was expressed as a standard deviation (SD) score for GA, with SGA defined as SD <−2, AGA as SD between −2 and 2, and LGA as SD >2. We selected the Apgar score at five minutes as it is reported to be a better predictor of long-term adverse health outcomes than the score at one minute [26]. Childhood infections were defined by diagnosis in the International Classification of Diseases (ICD) using the 9th and 10th revisions (ICD9: 001X -139W and ICD10: A000-B99 for any type of infections), and were, for cancer cases, included only if the infection occurred at least more than one month before diagnosis to exclude infections resulting from cancer.

Additionally, we investigated variables of smoking during gestational weeks 30–32 (yes, no), gestational diabetes (ICD10: O240; yes, no), child being diagnosed with a cancer predisposing syndrome [27,28] (information was available for: Down syndrome, ICD9: 758A and ICD10:Q90; Neurofibromatosis type 1, ICD9: 237H and ICD10: Q850; Congenital malformation syndromes involving early overgrowth, ICD9: 756W, 259W and ICD10: Q873; and Von Hippel-Lindau syndrome, ICD9: 759G and ICD10: Q858) [26,27], parents’ birth country and nationality (born to foreign parents, born to Swedish parents, or born to one Swedish and one foreign parent), maternal infection during pregnancy (ICD9: 001X–139W and ICD10: A000–B99; yes, no) and specific neonatal treatments. The above-listed characteristics were not included in the main statistical analyses (described below) due to low statistical power or extensive missing data.

Statistical analyses

In the present study, follow-up lengths vary considerably, with children born in the later part of the study period having significantly shorter follow-up compared to those born in the early years of the study. Traditional case-control analyses using logistic regression do not allow direct estimation of time-varying associations. Therefore, in the present study, the Cox proportional hazards regression models with child age as the underlying time scale were used to calculate hazard ratios (HR) for the association between perinatal characteristics and risk of childhood cancer. A similar statistical approach was also used by other similar studies [10,14,29]. The associations were examined for overall childhood cancer and separately for leukaemia, CNS tumours, lymphoma, and other cancer types combined (i.e., ICCC groups IV-XII, including unclassified; Table 2). The time scale (in years) was determined from birth date until the first childhood cancer diagnosis or censored at 19 years of age, emigration, or end of the follow-up on 31st of December 2021, whichever occurred first.

Table 2. Distribution of childhood cancer cases by year of birth, year of diagnosis, age at diagnosis, sex, and cancer type.

All childhood cancer cases, N (%) 1340 (100)
Birth year, N (%)
1989-1999 586 (44)
2000-2010 537 (40)
2011-2021 217 (16)
Year of first diagnosis, N (%)
1989-1999 191 (14)
2000-2010 475 (35)
2011-2021 736 (55)
Age at first diagnosis, N (%)
At birth 19 (1.4)
≤6 months 106 (8)
≤ 1 year 264 (20)
≤5 years 640 (48)
6-10 years 248 (18)
11-18 years 452 (34)
Average age at diagnosis, x―± SD 7.5 ± 6.0
Sex, N (%)
Male 7799 (53)
Female 6941 (47)
All Sex (N%)b Age at diagnosis (years; N%)b
(N%)a Male Female ≤5 6–10 11–18
ICCC groups:
I Leukaemia 345 (25) 192 (56) 153 (44) 223 (66) 62 (18) 60 (17)
II Lymphoma 152 (11) 92 (60) 60 (40) 47 (31) 37 (24) 68 (45)
III CNS tumors 328 (24) 168 (51) 160 (49) 125 (38) 84 (24) 119 (36)
IV Neuroblastoma & Other Peripheral Nervous Cell Tumors 71 (5) 47 (66) 24 (34) 64 (90) 5 (7) 2 (3)
V Retinoblastoma 25 (2) 17 (68) 8 (32) 25 (100) – –
VI Renal tumors 76 (6) 36 (47) 40 (53) 66 (87) 7 (9) 3 (4)
VII Hepatic tumors 12(1) 7 (58) 5 (42) 12 (100) – –
VIII Bone tumors 57(4) 35 (61) 22 (39) 6 (11) 15 (26) 36 (63)
IX Soft tissue tumors 67 (5) 35(53) 32 (47) 31 (46) 13 (19) 23 (34)
X Germ-cell, trophoblastic & other gonadal neoplasms 72(5) 40 (56) 32 (44) 22 (31) 8 (11) 42 (58)
XI Carcinomas & other malignant epithelial neoplasms 131(10) 38 (29) 93 (71) 9 (7) 16 (12) 106 (81)
XII Other & unspecified malignant neoplasms 11(0.8) 5 (45) 6 (54) 7 (64) 2 (18) 2 (18)
Not classified by ICCC 8(0.6) 4 (50) 4 (50) 6 (75) 2 (25) –

ICCC – International Childhood Cancer classification; CNS – central nervous system;

abased on all cancer diagnoses (n=1355; 15 children were diagnosed with more than one childhood cancer group);

bbased on all diagnoses within a specific cancer group;

ICCC groups marked in italic are within the manuscript combined into a group referred to as other cancer types combined.

We completed a crude Cox regression model for all perinatal characteristics separately. Subsequently, models with stepwise adjustments were conducted to identify possible influencing variables. The first model was adjusted for all parental characteristics (i.e., maternal cancer diagnosis, maternal and paternal age and education, parity, maternal BMI and maternal smoking), the second with further adjustment for pregnancy characteristics (i.e., assisted pregnancy with IVF and mode of delivery), and the third, in addition to parental and pregnancy characteristics, further adjustment for GA. This approach allowed us to investigate the risk of GA as a potential risk factor while also addressing its known potential as a mediating factor that might introduce collider bias [30]. The models were not assessed for characteristics or categories when there were fewer than ten observations among cases or controls [29].

Sensitivity analyses were performed by repeating the crude models for perinatal characteristics in the subset of individuals with complete data for all adjustment variables. Some perinatal characteristics were further analysed by a) excluding cases with a diagnosis at birth, b) excluding children diagnosed with cancer predisposed syndrome (Down syndrome, Neurofibromatosis type1, Congenital malformation syndromes involving early overgrowth, and Von Hippel-Lindau syndrome), c) stratification by age at diagnosis (i.e., ≤ 6 months, ≤1y or >1y for assessment of LGA and mechanical ventilation risk, while according to the statistical power the stratification of >6 months, 0–5y, 6–10y and 11–18y was used to assesses risk of planned caesarean delivery), d) adjustment for additional covariates to support the interpretation and discussion of the results. The proportional hazards assumption for each variable was tested by statistical tests and graphical diagnostics based on the scaled Schoenfeld residuals. All statistical analyses were performed using R software version 4.2.3 with RStudio version 2023.06.2 using two-tailed tests with a p-value of 0.05 as a criterion for statistical significance.

Results

In total, 1340 childhood cancer cases born between 1989 and 2021 in Southern Sweden were included. The distribution of cases by year of birth, child`s sex, age at diagnosis, and cancer types is presented in Table 2. The most common cancers were leukaemia (25%), CNS tumours (24%), and lymphoma (11%). There were more male (53%) compared to female (47%) childhood cancer cases. The average age at diagnosis was 7.5 years, with 48% of cases with the first diagnosis at or before the age of 5 years.

The distribution of perinatal characteristics between cases and controls for overall childhood cancer is presented in Table 3 and separately for leukaemia, CNS tumours, lymphoma, and other cancer types combined in S1 Table. Associations between perinatal characteristics and the risk of childhood cancer are shown in Table 4 for overall childhood cancer and summarised in Table 5 for leukaemia, CNS tumours, lymphoma, and other cancer types combined. The complete results are provided in Supporting information files: S2–S5 Tables.

Table 3. Distribution of studied perinatal characteristics between cases and controls within FeToxCancer study.

Perinatal characteristics FeToxCancer study
Cases (n = 1340)
N(%a)*
Controls (n = 13400)
N(%a)
Maternal cancer
No 1157 (86) 11654 (87)
Yes 183 (14) 1746 (13)
Maternal age (years)
<25 230 (17) 2423 (18)
25-34 889 (66) 8849 (66)
≥35 221 (17) 2128 (16)
Paternal age (years)
<25 96 (7) 914 (7)
25-34 757 (56) 7762 (58)
≥35 475 (35) 4613 (34)
missing 12 (1) 111 (1)
Maternal education
Primary 120 (9) 1319 (10)
Secondary 567 (42) 5580 (41)
Postsecondary 647 (48) 6379 (48)
missing 6 (0.4) 122 (0.9)
Paternal education
Primary 185 (14) 1832 (14)
Secondary 654 (49) 6567 (50)
Postsecondary 486 (37) 4763 (36)
missing 15 (0.2) 238 (1)
Parity (birth order)
1 571 (43) 5817 (43)
2 488 (36) 4847 (36)
≥3 281 (21) 2736 (21)
Maternal BMI (kg/m2)b
<18.5 34 (3) 294 (2)
18.5–24.9 677 (51) 7016 (52)
25–29.9 284 (21) 2724 (20)
≥30 127 (9) 1186 (9)
missing 218 (16) 2180 (16)
Maternal smoking b
No 1098 (82) 11078 (83)
Yes 182 (14) 1867 (14)
missing 60 (4) 455 (3)
Assisted pregnancy IVF
No 1314 (98) 13110 (98)
Yes 26 (2) 290 (2)
Mode of delivery
Vaginal 1068 (80) 10896 (81)
caesarean elective 73 (5) 715 (5)
caesarean emergency 122 (9) 1043 (8)
forceps or vacuum 77 (6) 746 (6)
GA (weeks)
<37 100 (7) 832 (6)
37–41 1157 (86) 11683 (87)
≥42 82 (7) 885 (7)
Birthweight for GA c
AGA 1200 (90) 12225 (91)
SGA 56 (4) 541 (4)
LGA 76 (6) 591 (4)
Missing 8 (0.6) 43 (0.3)
Child infection d
No 1247 (93) 12458 (93)
Yes 42 (3) 432 (3)
missing 51(4) 510 (4)
5min-Apgar
≥7 1307 (98) 13195 (99)
<7 25 (2) 149 (1)
missing 8 (0.6) 56 (0.4)
Neonatal care e
No 869 (65) 9077 (68)
Yes 145 (11) 1063 (8)
missing 326 (24) 3260 (24)

IVF – in vitro fertility.

abased on non-missing data;

bmaternal body mass index (BMI, kg/m2) and smoking status at enrolment into maternal health care.

cbased on weight, sex, GA and calculated according to Marsál et al., 1996.

dany infection during first year of birth.

edata available since 2002.

*According to any cancer type, distributions for leukaemia, CNS tumour, lymphoma and other cancer types combined are presented in S1 Table.

Table 4. Associations of perinatal characteristics with the risk of overall childhood cancer.

Perinatal characteristics Crude HR (95%CI) Crude HR (95%CI)
Complete dataa
1st Model
Adj HR (95%CI)
2nd Model
Adj HR (95%CI)
3rd Model
Adj HR (95%CI)
Parental characteristics
Maternal cancer, N 14740/1340 11816/1078 11816/1078 11816/1078 11816/1078
No Ref Ref Ref Ref Ref
Yes 0.99 (0.84, 1.15) 0.99 (0.83, 1.18) 1.00 (0.84, 1.19) 1.00 (0.84, 1.19) 1.00 (0.84, 1.19)
Maternal age (years), N 14740/1340 11816/1078 11816/1078 11816/1078 11816/1078
<25 Ref Ref Ref Ref Ref
25–34 1.08 (0.93, 1.24) 1.10 (0.94, 1.31) 1.11 (0.91, 1.35) 1.10 (0.91, 1.34) 1.10 (0.91, 1.34)
≥35 1.16 (0.97, 1.40) 1.15 (0.94, 1.42) 1.11 (0.85, 1.44) 1.09 (0.83, 1.42) 1.09 (0.83, 1.42)
Paternal age (years), N 14617/1328 11816/1078 11816/1078 11816/1078 11816/1078
<25 Ref Ref Ref Ref Ref
25–34 0.95 (0.76, 1.18) 0.98 (0.77, 1.26) 0.91 (0.69, 1.20) 0.91 (0.69, 1.20) 0.91 (0.69, 1.20)
≥35 1.04 (0.83, 1.29) 1.10 (0.85, 1.41) 1.00 (0.74, 1.36) 1.01 (0.74, 1.36) 1.01 (0.74, 1.36)
Maternal education, N 14612/1334 11816/1078 11816/1078 11816/1078 11816/1078
Primary Ref Ref Ref Ref Ref
Secondary 1.08 (0.88, 1.32) 0.98 (0.79, 1.22) 0.96 (0.77, 1.20) 0.96 (0.77, 1.21) 0.96 (0.77, 1.21)
Postsecondary 1.13 (0.93, 1.37) 1.10 (0.82, 1.26) 0.98 (0.77, 1.24) 0.98 (0.77, 1.25) 0.98 (0.77, 1.25)
Paternal education, N 14487/1325 11816/1078 11816/1078 11816/1078 11816/1078
Primary Ref Ref Ref Ref Ref
Secondary 0.98 (0.83, 1.16) 1.02 (0.85, 1.22) 1.01 (0.84, 1.23) 1.01 (0.84, 1.22) 1.01 (0.84, 1.22)
Postsecondary 1.05 (0.84, 1.30) 1.04 (0.86, 1.26) 1.01 (0.82, 1.25) 1.02 (0.82, 1.25) 1.02 (0.82, 1.25)
Parity, N 14740/1340 11816/1078 11816/1078 11816/1078 11816/1078
1 Ref Ref Ref Ref Ref
2 1.03 (0.91, 1.16) 1.05 (0.91, 1.19) 1.02 (0.88, 1.13) 1.03 (0.90, 1.19) 1.03 (0.90, 1.19)
≥3 1.04 (0.89, 1.20) 1.00 (0.86, 1.18) 0.95 (0.79, 1.13) 0.97 (0.81, 1.16) 0.97 (0.81, 1.16)
Maternal BMI (kg/m2)b, N 12342/1122 11816/1078 11816/1078 11816/1078 11816/1078
<18.5 1.20 (0.84, 1.71) 1.20 (0.84, 1.71) 1.23 (0.86, 1.76) 1.24 (0.87, 1.77) 1.23 (0.86, 1.73)
18.5–24.9 Ref Ref Ref Ref Ref
25–29.9 1.15 (1.03, 1.33)* 1.15 (1.00, 1.32)* 1.15 (1.00, 1.33)* 1.12 (0.96, 1.32) 1.11 (0.94, 1.37)
≥30 1.21 (0.99, 1.47) 1.21 (1.00, 1.47) 1.21 (0.99, 1.47) 1.19 (0.98, 1.44) 1.19 (0.98, 1.45)
Maternal smoking b , N 14225/1280 11816/1078 11816/1078 11816/1078 11816/1078
No Ref Ref Ref Ref Ref
Yes 0.90 (0.77, 1.05) 0.90 (0.75, 1.08) 0.91 (0.76, 1.10) 0.91 (0.76, 1.10) 0.91 (0.76, 1.10)
Pregnancy characteristics
Assisted pregnancy IVF, N* 14740/1340 11816/1078 11816/1078 11816/1078 11816/1078
No Ref Ref Ref Ref Ref
Yes 0.96 (0.65, 1.42) 0.92 (0.60, 1.41) 0.87 (0.57, 1.34) 0.86 (0.56, 1.32) 0.85 (0.55, 1.31)
Mode of delivery, N* 14740/1340 11816/1078 11816/1078 11816/1078 11816/1078
Vaginal no instruments Ref Ref Ref Ref Ref
caesarean elective 1.11 (0.87, 1.41) 1.13 (0.87, 1.37) 1.10 (0.85, 1.43) 1.11 (0.85, 1.44) 1.09 (0.84, 1.42)
caesarean emergency 1.26 (1.04, 1.51)* 1.24 (1.00, 1.50)* 1.19 (0.96, 1.48) 1.19 (0.97, 1.48) 1.17 (0.94, 1.46)
forceps or vacuum 1.08 (0.86, 1.36) 1.11 (0.86, 1.42) 1.13 (0.86,1.46) 1.13 (0.87, 1.46) 1.13 (0.87, 1.46)
Neonatal characteristics
GA (weeks), N 14730/1340 11816/1078 11816/1078 11816/1078 11816/1078
<37 1.19 (0.97, 1.47) 1.18 (0.93, 1.50) 1.17 (0.93, 1.49) 1.14 (0.89, 1.45) 1.14 (0.89, 1.45)
37–41 Ref Ref Ref Ref Ref
≥42 0.93 (0.75, 1.17) 0.98 (0.77, 1.26) 0.98 (0.77, 1.25) 0.97 (0.76, 1.23) 0.97 (0.76, 1.23)
Birthweight for GA c , N 14689/1332 11816/1078 11816/1078 11816/1078 11816/1078
AGA Ref Ref Ref Ref Ref
SGA 1.04 (0.80, 1.36) 0.97 (0.70, 1.33) 0.97 (0.70, 1.34) 0.95 (0.67, 1.30) 0.93 (0.67, 1.28)
LGA 1.30 (1.03, 1.64)* 1.37 (1.08, 1.76)* 1.32 (1.03, 1.70)* 1.32 (1.02, 1.68)* 1.31 (1.02, 1.68)*
Child infection-I d , N 14179/1289 11361/1039 11361/1039 11361/1039 11361/1039
No Ref Ref Ref Ref Ref
Yes 0.95 (0.70, 1.30) 1.04 (0.75, 1.46) 1.05 (0.74, 1.47) 1.05 (0.75, 1.47) 0.95 (0.49, 1.85)
5-min Apgar, N 14676/1332 11773/1071 11773/1071 11773/1071 11773/1071
≥7 Ref Ref Ref Ref Ref
<7 1.73 (1.16, 2.57)** 1.72 (1.16, 2.56)** 1.61 (1.02, 2.55)* 1.53 (0.97, 2.43) 1.50 (0.94, 2.38)
Neonatal care e , N 11154/1014 9832/895 9832/895 9832/895 9832/895
No Ref Ref Ref Ref Ref
Yes 1.40 (1.17, 1.66)*** 1.30 (1.07, 1.57)** 1.28 (1.05, 1.56)* 1.24 (1.01, 1.52)* 1.25 (1.00, 1.56)*

N – number of total observations/number of events; GA – gestational age; IVF – in vitro fertilisation; BMI – body mass index; AGA – adequate for GA, SGA– small for GA, LGA – large for GA; NA – less than 10 observations;

*** p <0.001, ** p <0.01, * p <0.05;

models 1–3: shaded are perinatal characteristics used as adjustment covariates in the respective model.

aaccording to complete data for all used adjustment covariates; bsmoking and BMI at the time of enrolment into maternal health care; ccalculated according to birthweight, sex and gestational age; ddata according to the National Patient Register (in-patient care; since 1990); edata available since 1995

Table 5. Summarised associations of perinatal characteristics with the risk of leukaemia, CNS tumour, lymphoma and other cancer types combined (i.e., ICCC group IV-XII including unclassified diagnoses).

Perinatal characteristics Crude HR (95%CI Crude HR (95%CI)
Complete dataa
Model 1
HR (95%CI)
Model 2
HR (95%CI)
Model 3
HR (95%CI)
LEUKAEMIA
Parental characteristics
Maternal BMI (kg/m2)a, N 3268/ 300 3124/291 3124/291 3124/291 3124/291
<18.5 2.34 (1.38, 3.97)** 2.32 (1.34, 4.00)** 2.44 (1.41, 4.23)** 2.44 (1.41, 4.23)** 2.43 (1.40, 4.22)**
18.5–24.9 Ref Ref Ref Ref Ref
25–29.9 1.24 (0.96, 1.62) 1.28 (0.98, 1.66) 1.24 (0.94, 1.62) 1.23 (0.94, 1.61) 1.23 (0.94, 1.61)
≥30 0.95 (0.64, 1.41) 0.97 (0.65, 1.44) 0.94 (0.63, 1.40) 0.92 (0.62, 1.38) 0.92 (0.62, 1.38)
Neonatal characteristics
Birthweight for GA, N 3782/343 3114/290 3114/290 3114/290 3114/290
AGA Ref Ref Ref Ref Ref
SGA 1.07 (0.63, 1.79) 0.97 (0.54, 1.73) 0.96 (0.53, 1.72) 0.93 (0.51, 1.68) 0.94 (0.52, 1.72)
LGA 1.66 (1.10, 2.51)* 1.56 (1.01, 2.46)* 1.58 (1.02, 2.51)* 1.59 (1.01, 2.52)* 1.58 (1.01, 2.51)*
CNS TUMORS
Parental characteristics
Maternal BMI (kg/m2)b, N 3027/275 2911/ 264 2911/ 264 2911/ 264 2911/ 264
<18.5 0.86 (0.35, 2.09) 0.94 (0.39, 2.29) 0.99 (0.41, 2.43) 0.99 (0.40, 2.42) 0.99 (0.41, 2.43)
18.5–24.9 Ref Ref Ref Ref Ref
25–29.9 1.09 (0.82, 1.45) 1.15 (0.87, 1.53) 1.19 (0.88, 1.57) 1.18 (0.88, 1.57) 1.17 (0.88, 1.57)
≥30 1.31 (1.00, 1.99)* 1.41 (1.01, 2.06)* 1.51 (1.04, 2.21)* 1.52 (1.04, 2.22)* 1.51 (1.04, 2.21)*
LYMPHOMA
Parental characteristics
Paternal age (years), N 1673/152 1322/115 1322/115 1322/115 1322/115
<25 Ref Ref Ref Ref Ref
25-34 0.76 (0.44, 1.30) 0.66 (0.36, 1.21) 0.46 (0.21, 0.97)* 0.44 (0.20, 0.94)* 0.44 (0.20, 0.94)*
≥35 0.54 (0.29, 0.99)* 0.51 (0.26, 1.00) 0.30 (0.13, 0.73)** 0.29 (0.12, 0.71)** 0.29 (0.12, 0.71)**
Maternal BMI (kg/m2)c, N 1372/124 1322/115 1322/115 1322/115 1322/115
<18.5 NA NA NA NA NA
18.5–24.9 Ref Ref Ref Ref Ref
25–29.9 1.31 (0.87, 1.98) 1.31 (0.87, 1.99) 1.39 (0.91, 2.12) 1.41 (0.91, 2.17) 1.41 (0.91, 2.17)
≥30 2.31 (1.41, 3.77)*** 2.10 (1.24, 3.54)*** 2.27 (1.33, 3.87)** 2.26 (1.31, 3.87)** 2.26 (1.31, 3.88)**
OTHER CANCER TYPES COMBINED
Pregnancy characteristics
Mode of delivery, N 5687/517 4491/411 4491/411 4491/411 4491/411
Vaginal no instruments Ref Ref Ref Ref Ref
caesarean elective 1.45 (1.03, 2.05)* 1.55 (1.07, 2.26)* 1.57 (1.08, 2.29)* 1.57 (1.07, 2.29)* 1.54 (1.06, 2.25)*
caesarean emergency 1.29 (0.95, 1.75) 1.39 (1.00, 1.94)* 1.43 (1.02, 2.00)* 1.45 (1.04, 2.04)* 1.39 (0.98, 1.97)
forceps or vacuum 0.98 (0.66, 1.48) 1.06 (0.69, 1.63) 1.11 (0.71, 1.72) 1.11 (0.71, 1.73) 1.11 (0.87, 1.82)
Neonatal characteristics
5-min Apgar, N 5666/514 4481/409 4481/409 4481/409 4481/409
≥7 Ref Ref Ref Ref Ref
<7 2.39 (1.38, 4.14)** 2.55 (1.36, 4.77)** 2.60 (1.38, 4.91)** 2.23 (1.17, 4.38)* 2.16 (1.12, 4.15)*
Neonatal care d , N 4103/373 3604/326 3604/326 3604/326 3604/326
No Ref Ref Ref Ref Ref
Yes 1.49 (1.13, 2.00)** 1.48 (1.10. 1.99)** 1.50 (1.11, 2.02)** 1.38 (1.01, 1.89)* 1.40 (1.02, 1.97)*

N, n of total observations/n of events;BMI- maternal body mass, AGA – adequate for GA, SGA – small for GA, LGA – large for GA; NA – less than 10 observations in either cases or controls; *** p <0.001, ** p <0.01 and * p <0.5); aaccording to complete data for all used adjustment covariates; bat enrolment into maternal health care, ccalculated according to birthweight, sex, and gestational age; ddata available since 1995.

Model 1: adjusted for maternal cancer, maternal and paternal age, maternal and paternal education, parity, maternal BMI and maternal smoking during early pregnancy.

Model 2: adjusted for variables in 1st model and additionally for IVF and mode of delivery.

Model 3: adjusted for all variables in 2nd model and additionally for gestational age;

Associations between neonatal characteristics and risk of childhood cancer

Crude and adjusted models showed a higher risk of overall childhood cancer among children born LGA compared to AGA (adjusted HR, 95%CI: 1.32, 1.02–1.69; Table 4). Additionally, LGA was associated with increased risk of leukaemia (adjusted HR, 95%CI: 1.58, 1.01–2.51), and somewhat increased risk for other cancer types combined (adjusted HR, 95%CI: 1.45, 0.98–2.14). Being diagnosed with cancer at birth (S1 Fig), diagnosed with cancer predisposing syndrome (S6 Table), or additional adjustment for gestational diabetes (S7 Table) had no significant effect on observed associations. Stratification by age at diagnosis showed a stronger association for LGA and risk of overall childhood cancer for diagnoses ≤ 1 year (adjusted HR, 95%CI: 2.06, 1.29–2.31), and particularly ≤6 months (adjusted HR, 95%CI: 3.61, 1.87–6.97) compared to those diagnosed later (adjusted HR, 95%CI: 1.14, 0.84–1.54) (Fig 2).

Fig 2. Associations of birthweight for GA (a), mechanical ventilation treatment (b) and planned caesarean delivery (c) with the risk of overall childhood cancer, and other cancer types combined, stratified by age at diagnosis.

Fig 2

(*** p <0.001, ** p <0.01, * p <0.05; a– adjusted according to model 3, NA – not available due to low observation number (i.e., < 10); AGA – adequate for GA, SGA – small for GA, LGA – large for GA; other types combined – ICCC group IV-XII, including unclassified diagnoses).

A 5-min Apgar score <7 was associated with increased risk of overall childhood cancer and other cancer types combined (crude HR, 95%CI: 1.73, 1.16–2.57; and 2.39,1.38–4.14, respectively). However, after adjustment for pregnancy characteristics and GA, only the association with other cancers combined remained (adjusted HR, 95%CI: 2.16, 1.12–4.15; Tables 4 and 5). Moreover, the latter association remained when excluding cases diagnosed with cancer at birth (S1 Fig), diagnosed with cancer predisposing syndromes (S6 Table), as well as after additional adjustment for admission to neonatal care, and birthweight for GA (Table a in S8 Table). Moreover, the distribution of cancer cases with low 5-min Apgar was higher among those diagnosed ≤ 6 months or ≤1 year when compared to those diagnosed later (6% 3% and 1.5%, respectively, Table b in S8 Table).

Admission into neonatal care was associated with a higher risk of overall childhood cancer (adjusted HR, 95%CI: 1.25,1.00–1.56, Table 4) and other cancer types combined (adjusted HR, 95%CI: 1.40, 1.00–1.97, Table 4). Moreover, after the exclusion of cases diagnosed with cancer at birth, only the association with other cancer types combined remained (S1 Fig), while no association remained significant after the exclusion of children diagnosed with cancer predisposing syndromes (S6 Table). Due to low statistical power, we were unable to further explore specific neonatal therapies (Table a in S9 Table), except for mechanical ventilation (Table b in S9 Table). The latter was associated with a higher risk of overall childhood cancer and other cancer types combined (adjusted HR, 95%CI: 1.88, 1.39–2.53 and 2.15, 1.29–3.56, respectively; S9 Table). This association was independent of cancer cases diagnosed at birth (S1 Fig), diagnosis with cancer predisposing syndromes, Apgar score, or birthweight for GA (S9 Table). Moreover, treatment by mechanical ventilation indicated an increased risk of overall cancer, especially among children diagnosed at ≤ 1 year of age (Fig 2).

No associations were observed between early childhood infections and the risk of overall childhood cancer (Table 4) or specific cancer types (S2–S5 Tables).

Associations between parental and pregnancy characteristics and risk of childhood cancer

High maternal BMI (overweight or obese) was associated with a higher risk of CNS tumors (adjusted HR 95%CI: 1.51, 1.04–2.21), lymphoma (adjusted HR 95%CI: 2.31 1.41–3.77), and somewhat increased risk of overall cancer (adjusted HR 95%CI: 1.11, 0.94–1.37; Tables 4 and 5), while low maternal BMI (underweight) was associated with a higher risk of leukaemia (adjusted HR 95%CI: 2.43, 1.40–4.22). Associations were independent of diagnosis with cancer predisposing syndromes (S6 Table), birthweight for GA, or gestational diabetes (S10 Table).

Caesarean delivery (CD), compared with spontaneous vaginal delivery, was associated with an increased risk of childhood cancer. Emergency CD was associated with an increased risk of overall childhood cancer (crude HR 95%CI: 1.26, 1.04–1.51), and both planned and emergency CD with increased risk of other cancer types combined (crude HR 95%CI: 1.45, 1.03–2.05 and 1.29, 1.01–1.75, respectively). After adjustments, only the association for planned CD and risk of other cancer types combined remained (adjusted HR 95%CI: 1.52 1.04–2.22) and was also independent of cancer cases diagnoses at birth (S1 Fig), at ≤6 months of age (Fig 2), diagnosis of cancer predisposing syndromes (S6 Table), and of birthweight for GA and Apgar score (S11 Table).

Furthermore, a paternal age of 35y or more compared to below 25y was associated with a reduced risk of lymphoma (adjusted HR 95%CI: 0.29, 0.12–0.71; Table 5). However, an analysis with a 5-year age advancement did not confirm these results (S12 Table).

We observed no associations between the risk of childhood cancer and other parental and pregnancy characteristics, except for children being diagnosed with cancer predisposing syndromes, which showed considerably higher risk of childhood cancer (HR 95%CI: 10.9, 7.79–15.5) (Tables 3 and S13). Sensitivity analyses conducted on participants with complete data showed no significant influence of missing data on the results (Tables 3 and 4).

Discussion

We identified several perinatal characteristics independently associated with the risk of overall childhood cancer as well as specific cancer types. Most of the associations were observed for characteristics reflecting neonatal distress, including LGA, low 5-min Apgar score, and neonatal care treatment, which were associated with increased risk of overall childhood cancer, leukaemia, and/or other cancer types combined. Additionally, high maternal BMI was associated with an increased risk of lymphoma and CNS tumors, low maternal BMI with an increased risk of leukaemia, and planned caesarean delivery with an increased risk of other cancer types combined. While prior studies have reported associations between these characteristics and childhood cancer risk, none are yet considered established risk factors [4,10].

Associations of neonatal characteristics and risk of childhood cancer

Several epidemiological studies have linked LGA with increased risk of leukaemia, lymphoma, CNS, kidney, liver, germ cell, and soft tissue tumours [10,31–35], while SGA has been linked with a higher risk of leukaemia, lymphoma, and CNS tumours [18,31,36]. In the present study, LGA demonstrated an increased risk of overall childhood cancer and leukaemia, and to some extent other cancer types combined, while no associations were observed between SGA and overall childhood cancer or cancer types. Foetal growth is a complex process influenced by the interplay of (epi)genetic, hormonal, and nutritional factors and the biological mechanisms linking foetal growth to the risk of childhood cancer remain unknown. Current principal hypotheses suggest that larger organs present more cells at risk of mutagenesis and that increased intrauterine cell proliferation may result from overexpression of growth factors like insulin-like growth factors I and II [10,18,31,33]. Moreover, maternal BMI and gestational diabetes were proposed as potential underlying factors of LGA-childhood cancer associations [37,38]. In this study, both BMI and gestational diabetes were associated with LGA (S14 Table), but none explained the associations between LGA and childhood cancer. Another hypothesis suggests the reverse effect of an in-utero present tumour on a foetus’s growth [18]. Moreover, LGA has been highlighted as a risk factor for particularly early-diagnosed childhood cancer [31,33]. While exclusion of cases diagnosed at birth did not influence our results, we observed up to a three-fold increase in the risk of childhood cancer among children diagnosed ≤ 6 months. LGA could also result from certain underlying genetic syndromes (e.g., overgrowth Beckwith–Wiedemann syndrome) [39], which are well-known independent risk factors for certain childhood cancer types [39,40]. Nevertheless, the exclusion of children diagnosed with cancer predisposing syndromes (i.e., Down syndrome, Neurofibromatosis type 1, Congenital malformation syndromes involving early overgrowth, and Von Hippel-Lindau syndrome) did not affect observed associations with LGA.

A 5-min Apgar score <7 was associated with increased risk of all other cancers combined, however, its low prevalence (1.2%) prevented assessment of individual risks for CNS tumours, leukaemia, and lymphoma. Previous studies linked low 5-min Apgar scores with an increased risk of neuroblastoma, renal, CNS, and liver tumours [14,19,41–43] with studies on Swedish-Danish [14] and Brazilian cohorts [43] showing a stronger association among children diagnosed <6 months of age. Similarly, in our study, low 5-min Apgar scores were more frequent in children diagnosed ≤6 months than in those diagnosed later. This could imply a shared in-utero initiated aetiology of low Apgar score and childhood cancer [14]. As shown in this study, low Apgar scores often co-occur with SGA and neonatal treatments [14], both linked to higher childhood cancer risk [36,44,45]. However, in our study, these factors do not explain the observed association between Apgar scores and the increased risk of other cancers combined.

Various studies have suggested long-term adverse health effects of neonatal treatments, including risk for malignancy [19,46–48]. A Finnish study reported an association between mechanical ventilation, resuscitation, and antibiotic therapy, with risk of overall childhood cancer, irrespective of GA [19], while the increased risk of childhood cancer following oxygen supplementation was also reported by others [45,49]. In this study, overall neonatal treatments were associated with an increased risk of other cancer types combined. However, this association disappeared after excluding children diagnosed with cancer predisposing syndromes. Low statistical power hampered our investigation of the specific above-mentioned neonatal treatments, except for mechanical ventilation, which indicated a higher risk of overall childhood cancer and other cancer types combined. Mechanical ventilation follows a diagnosis of neonatal hypoxia and asphyxia, which often co-occur with cancer risk factors such as low Apgar score and high birthweight [19,49]. In this study, the association between mechanical ventilation and childhood cancer risk was independent of those factors as well as of the diagnosis of cancer predisposing syndromes. Oxygen supplementation can generate reactive oxygen species, implicated in carcinogenesis and cancer progression, though evidence remains conflicting [50]. As concluded by other studies, observed associations do not prove causation, and oxygen supplementation should be considered only as potentially carcinogenic [19,49]. Neonatal intubation is commonly accompanied by diagnostic radiation, another possible carcinogenic risk factor [4,19]. Other unmeasured factors—such as pregnancy complications, maternal health conditions, and congenital malformations—may predispose infants to both neonatal therapies and childhood cancer, suggesting possible reverse causality. Thus, the link between neonatal therapies and childhood cancer warrants further study.

Parental and pregnancy characteristics and risk of childhood cancer

Maternal overweight or obesity was previously associated with an increased risk of childhood cancer, including leukaemia, CNS tumours, and retinoblastoma [11,51–53], while others reported null associations [11,31,54,55]. In our study, we observed an association between maternal obesity in early pregnancy and a higher risk of CNS tumours and lymphoma as well as a trend of maternal overweight being associated with increased risk of leukaemia. Those associations were independent of gestational diabetes or birthweight for GA; characteristics commonly associated with maternal BMI and childhood cancer [37]. Additionally, we observed a higher risk of leukaemia among children born to underweight mothers. Maternal underweight has been linked to an increased risk of germ cell tumours and overall cancer in some studies [51,54], whereas others have reported null associations [11]. The inconsistent results across studies could result from variations in study designs or methods in assessing BMI as a risk factor (e.g., continuous, 5-unit change, or categories).

The mechanisms linking maternal malnutrition to childhood cancer remain unclear, though altered foetal or neonatal epigenetic programming is the leading hypothesis [37]. Maternal obesity has been associated with differential DNA methylation in newborns, including cancer-related genes such as IGF1, IGF2, and MAD1L1 [56–58]. A recent longitudinal study found persistent methylation changes linked to metabolic and developmental pathways through the first year of life [59], suggesting lasting epigenetic effects. Similarly, offspring of underweight women may experience epigenetic dysregulation in growth and metabolism genes [60], though evidence is limited and largely from low-income settings. With maternal overweight and obesity rising globally, from 25% to 46% in Sweden between 1992 and 2022 [61], improving maternal nutrition before and during pregnancy could be an important cancer prevention strategy.

Moreover, we observed caesarean delivery to be associated with an increased risk of overall childhood cancer. The association was observed particularly for planned CD and risk of other cancer types combined, which was independent of additional adjustment for 5-min Apgar score or birthweight for GA. Globally, the caesarean delivery rate is increasing [62] and so is the number of studies reporting its association with the risk of childhood cancer, particularly for leukaemia, but also CNS, liver, and other solid tumours [12,63–66]. While a large cohort with over 11 thousand across Sweden, Denmark and Finland reported null associations [67]. However, in line with our results, several studies reported planned rather than emergency CD, as significantly associated with childhood cancer [63–66,68]. Commonly suggested mechanisms are limited exposure to maternal vaginal microflora and lower stress hormone levels (e.g., cortisol, adrenaline) in neonates born via planned CD, compared to those born via emergency CD or vaginal delivery [64,66,69]. Both low microbial diversity as well as hypocortisolism result in a weakened neonatal immune system [70], which might consequently contribute to a higher risk of cancer development [64,66,71]. Marcoux et al., 2023 [64] suggested that including early-detected cases may have biased prior CD associations through perinatal confounding. In contrast, excluding early-onset cases in our study strengthened the association between planned CD and risk of other combined cancer types. This discrepancy may reflect CD type, as Marcoux et al. (2022) did not distinguish emergency from planned CD, which represent different exposure scenarios [72]. In summary, emerging evidence and plausible mechanisms linking planned CD to childhood cancer highlight the need to reduce non-medically indicated CDs, commonly referred to as “caesarean on maternal request”.

Parental age and childhood cancer risk have been widely studied, with mixed findings ranging from increased risk with advanced parental age [16,72–75] to no associations [12,76,77]. In the present study, higher paternal age (25–34 and ≥35 vs. < 25) was linked to lower lymphoma risk, but this was not confirmed using 5-year age increments. Prior evidence on paternal age and lymphoma is also inconsistent [16,73,78]; the observed protective role of paternal age on the risk of lymphoma in our study should be interpreted with caution.

Strength and limitations of the study

The study’s strengths include the use of several high-quality health- and population-based registries, enabling the investigation of several perinatal factors and adjustment for relevant confounders. Additionally, objectively and prospectively collected registry data eliminated the risk of selection and recall bias. Moreover, the availability of data for some genetic syndromes (i.e., Down syndrome, Neurofibromatosis type 1, Congenital malformation syndromes involving early overgrowth (Beckwith-Wiedemann syndrome), and Von Hippel-Lindau syndrome) enabled us to make additional adjustments for these known cancer-predisposing syndromes. The main limitation of the FeToxCancer study is a low number of cases per specific cancer types, which resulted in low statistical power and hindered a more comprehensive analysis of perinatal characteristics with the risk of specific cancer types. The statistical analysis of this study includes multiple comparisons, increasing the risk of false positives. However, given the limited statistical power, lowering the significance threshold could potentially overlook meaningful associations. Therefore, we chose to interpret the results cautiously in the context of existing literature rather than adjust for multiple comparisons. Nevertheless, the possibility of false positives still exists. Preterm birth reflects both immaturity and various pathological factors, with currently unclear links to GA. Consequently, in studies on neonatal outcomes, adjusting for GA, as a potential mediator factor, may introduce collider bias [30]. In our study, we examined numerous maternal and pregnancy characteristics, including GA, as potential risk factors for childhood cancer, many of which have unclear relationships with GA. To assess GA both as a potential risk factor and a confounder (e.g., neonatal care, mechanical ventilation therapy) while addressing collider bias, we fitted models with and without GA, as previously proposed by Wilcox et al. (2011) [30]. Lastly, missing data for some characteristics (e.g., BMI), as well as a lack of information on other risk factors such as family history, and environmental exposures, might represent bias in the present study.

Conclusions

The present study provides support for several perinatal characteristics previously associated with the risk of childhood cancer. The reported results strongly highlight the significance of the perinatal period as a critical window, particularly for early-onset childhood cancer. Furthermore, our study contributes additional insight into risk prediction as well as provides knowledge for evidence-based care of mothers and newborns, which may facilitate the improvement of preventive measures.

Supporting information

S1 Table. Distribution of studied perinatal characteristics between cases of leukaemia, CNS tumours, lymphoma and other cancer types combined and matching controls.

(DOCX)

pone.0333752.s001.docx (36.2KB, docx)
S2 Table. Associations of perinatal characteristics with leukaemia.

(DOCX)

pone.0333752.s002.docx (34.5KB, docx)
S3 Table. Associations of perinatal characteristics with CNS tumours.

(DOCX)

pone.0333752.s003.docx (34.8KB, docx)
S4 Table. Associations of perinatal characteristics with lymphoma.

(DOCX)

pone.0333752.s004.docx (34.5KB, docx)
S5 Table. Associations of perinatal characteristics with other cancer types combined (ICCC groups IV to XII including by ICCC unclassified).

(DOCX)

pone.0333752.s005.docx (34.4KB, docx)
S6 Table. Associations of perinatal characteristics with risk of childhood cancer and cancer types after exclusion of children diagnosed with cancer-predisposing syndromes#.

(DOCX)

pone.0333752.s006.docx (38.2KB, docx)
S7 Table. Association of birthweight for GA with risk of overall childhood cancer and leukaemia after additional adjustment for gestational diabetes.

(DOCX)

pone.0333752.s007.docx (22.7KB, docx)
S8 Table. Association of 5-min Apgar with other cancer types combined after additional adjustment for birthweight for GA and neonatal care (a) and distribution of 5-min Apgar according to the age at diagnosis (b).

(DOCX)

pone.0333752.s008.docx (23.7KB, docx)
S9 Table. Distribution and association of specific neonatal therapies with overall childhood cancer (a), and association of mechanical ventilation with other cancer types (b).

(DOCX)

pone.0333752.s009.docx (29.1KB, docx)
S10 Table. Association of maternal BMI with leukemia, CNS tumor and lymphoma after additional adjustment for birthweight for GA (a) or gestational diabetes (b).

(DOCX)

pone.0333752.s010.docx (23.6KB, docx)
S11 Table. Association between mode of delivery and risk of other cancer types combined after additional adjustment for birthweight for GA and 5-min Apgar score.

(DOCX)

pone.0333752.s011.docx (24.3KB, docx)
S12 Table. Association between parental 5-year advance in age with risk of childhood cancer and specific cancer types.

(DOCX)

pone.0333752.s012.docx (23.2KB, docx)
S13 Table. Distribution and associations of additionally tested perinatal characteristics with childhood cancer.

(DOCX)

pone.0333752.s013.docx (28.8KB, docx)
S14 Table. Associations of birthweight for GA with maternal BMI and Gestational diabetes (a) and of 5-min Apgar with birthweight for GA, gestational age and admission to neonatal care (b).

(DOCX)

pone.0333752.s014.docx (24.3KB, docx)
S1 Fig. Forest plot presenting associations of birthweight for GA, 5-min Apgar score, admission to neonatal care, mechanical ventilation treatment, and mode of delivery with the risk of overall childhood cancer, leukaemia or other cancer types combined after the exclusion of cancer cases diagnosed at birth (adjusted according to model 3; ** p < 0.01, *p < 0.05; other types combined– ICCC groups IV-XII including unclassified diagnoses; AGA – adequate for GA, SGA–small for GA, LGA–large for GA).

(DOCX)

pone.0333752.s015.docx (275.2KB, docx)

Data Availability

Due to the personal data collected and potentially identifying information l contained within the data, the data are available upon request. Ethical approval by the Swedish Ethical Review Authority may be necessary, and requests for data may be sent to: SOCIALSTYRELSEN Statistikavdelningen Enheten för Mikrodata 106 30 Stockholm email: socialstyrelsen@socialstyrelsen.se.

Funding Statement

1) -KB, -Grant No: Dnr 20 0825 Pj; -full name: Swedish Cancer Society, -URL: https://www.cancerfonden.se/om-oss/about -no 2) -KB; -Grant No: PR2020-0012; -full name: Swedish Childhood Cancer Foundation; -URL: https://www.barncancerfonden.se; -no 3) KB; -Grant No: 2022-Projekt0162; -Full name: ALF; -url: https://www.intramed.lu.se/en/research/alf-funding; -no 4) -KB, -Grant No: 2022-01-11:10, -full name: Sjöberg Foundation, -URL: https://sjobergstiftelsen.se/ -no.

References

  • 1.SBCR. Årsrapport 2022 Svenska Barncancerregistret. 2022.
  • 2.WHO. Framework: WHO global initiative for childhood cancer. In: CureAll framework: WHO global initiative for childhood cancer: increasing access, advancing quality, saving lives; 2021. p. 1–109.
  • 3.Huang J, Chan SC, Ngai CH, Lok V, Zhang L, Lucero-Prisno DE 3rd, et al. Global incidence, mortality and temporal trends of cancer in children: a joinpoint regression analysis. Cancer Med. 2023;12(2):1903–11. doi: 10.1002/cam4.5009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Alonso‐Luna O, Mercado‐Celis GE, Melendez‐Zajgla J, Zapata‐Tarres M, Mendoza‐Caamal E. The genetic era of childhood cancer: identification of high‐risk patients and germline sequencing approaches. Ann Hum Genet [Internet]. 2023;87(3):81–90. Available from: https://onlinelibrary.wiley.com/doi/10.1111/ahg.12502 [DOI] [PubMed] [Google Scholar]
  • 5.Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555(7696):321–7. doi: 10.1038/nature25480 [DOI] [PubMed] [Google Scholar]
  • 6.Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med [Internet]. 2015;373(24):2336–46. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1508054 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev. 2010;36(4):277–85. doi: 10.1016/j.ctrv.2010.02.003 [DOI] [PubMed] [Google Scholar]
  • 8.Anderson LM, Diwan BA, Fear NT, Roman E. Critical windows of exposure for children’s health: cancer in human epidemiological studies and neoplasms in experimental animal models. Environ Health Perspect. 2000;108 Suppl 3(Suppl 3):573–94. doi: 10.1289/ehp.00108s3573 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Greaves M. A causal mechanism for childhood acute lymphoblastic leukaemia. Nat Rev Cancer. 2018;18(8):471–84. doi: 10.1038/s41568-018-0015-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kampitsi CE, Nordgren A, Mogensen H, Pontén E, Feychting M, Tettamanti G. Neurocutaneous syndromes, perinatal factors, and the risk of childhood cancer in Sweden. JAMA Netw Open [Internet]. 2023;6(7):e2325482. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2807598 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Marley AR, Domingues A, Ghosh T, Turcotte LM, Spector LG. Maternal body mass index, diabetes, and gestational weight gain and risk for pediatric cancer in offspring: a systematic review and meta-analysis. JNCI Cancer Spectr. 2022;6(2). doi: 10.1093/jncics/pkac020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Onyije FM, Dolatkhah R, Olsson A, Bouaoun L, Deltour I, Erdmann F, et al. Risk factors for childhood brain tumours: a systematic review and meta-analysis of observational studies from 1976 to 2022. Cancer Epidemiol. 2024;88:102510. doi: 10.1016/j.canep.2023.102510 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Spector LG, Pankratz N, Marcotte EL. Genetic and nongenetic risk factors for childhood cancer. Pediatr Clin North Am. 2015;62(1):11–25. doi: 10.1016/j.pcl.2014.09.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Li J, Cnattingus S, Gissler M, Vestergaard M, Obel C, Ahrensberg J, et al. The 5-minute Apgar score as a predictor of childhood cancer: a population-based cohort study in five million children. BMJ Open. 2012;2(4):e001095. doi: 10.1136/bmjopen-2012-001095 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Lupatsch JE, Kreis C, Konstantinoudis G, Ansari M, Kuehni CE, Spycher BD. Birth characteristics and childhood leukemia in Switzerland: a register-based case-control study. Cancer Causes Control. 2021;32(7):713–23. doi: 10.1007/s10552-021-01423-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Domingues A, Moore KJ, Sample J, Kharoud H, Marcotte EL, Spector LG. Parental age and childhood lymphoma and solid tumor risk: a literature review and meta-analysis. JNCI Cancer Spectr. 2022;6(3). doi: 10.1093/jncics/pkac040 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Rossides M, Mogensen H, Kampitsi C-E, Talbäck M, Wiebert P, Tettamanti G, et al. Parental occupational exposure to metals and risk of cancer in the offspring: a register-based case-control study from Sweden. Eur J Cancer. 2023;191:113243. doi: 10.1016/j.ejca.2023.113243 [DOI] [PubMed] [Google Scholar]
  • 18.Schmidt LS, Schüz J, Lähteenmäki P, Träger C, Stokland T, Gustafson G, et al. Fetal growth, preterm birth, neonatal stress and risk for CNS tumors in children: a Nordic population- and register-based case-control study. Cancer Epidemiol Biomarkers Prev. 2010;19(4):1042–52. [DOI] [PubMed] [Google Scholar]
  • 19.Seppälä LK, Vettenranta K, Leinonen MK, Tommiska V, Madanat‐Harjuoja L. Preterm birth, neonatal therapies and the risk of childhood cancer. Int J Cancer [Internet]. 2021;148(9):2139–47. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ijc.33376 [DOI] [PubMed] [Google Scholar]
  • 20.Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol [Internet]. 2009;24(11):659–67. Available from: http://link.springer.com/10.1007/s10654-009-9350-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish cancer register – a sample survey for year 1998. Acta Oncol. 2009;48(1):27–33. doi: 10.1080/02841860802247664 [DOI] [PubMed] [Google Scholar]
  • 22.Cnattingius S, Källén K, Sandström A, Rydberg H, Månsson H, Stephansson O, et al. The Swedish medical birth register during five decades: documentation of the content and quality of the register. Eur J Epidemiol. 2023;38(1):109–20. doi: 10.1007/s10654-022-00947-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Eurostat. GISCO — Geodata for Territorial Units for Statistics (NUTS 3, 2021) [Internet]; 2021 [cited 2025 Dec 22]. Available from: https://ec.europa.eu/eurostat/web/gisco/geodata/statistical-units/territorial-units-statistics?utm_source=chatgpt.com
  • 24.Sprehe MR, Barahmani N, Cao Y, Wang T, Forman MR, Bondy M, et al. Comparison of birth weight corrected for gestational age and birth weight alone in prediction of development of childhood leukemia and central nervous system tumors. Pediatr Blood Cancer. 2010;54(2):242–9. doi: 10.1002/pbc.22308 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Maršál K, Persson P, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr. 1996;85(7):843–8. doi: 10.1111/j.1651-2227.1996.tb14164.x [DOI] [PubMed] [Google Scholar]
  • 26.Razaz N, Cnattingius S, Persson M, Tedroff K, Lisonkova S, Joseph KS. One-minute and five-minute Apgar scores and child developmental health at 5 years of age: a population-based cohort study in British Columbia, Canada. BMJ Open. 2019;9(5):e027655. doi: 10.1136/bmjopen-2018-027655 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kratz CP, Jongmans MC, Cavé H, Wimmer K, Behjati S, Guerrini-Rousseau L, et al. Predisposition to cancer in children and adolescents. Lancet Child Adolesc Health. 2021;5(2):142–54. doi: 10.1016/S2352-4642(20)30275-3 [DOI] [PubMed] [Google Scholar]
  • 28.Roganovic J. Genetic predisposition to childhood cancer. World J Clin Pediatr. 2024;13(3). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Crump C, Sundquist K, Sieh W, Winkleby MA, Sundquist J. Perinatal and family risk factors for non-Hodgkin lymphoma in early life: a Swedish national cohort study. J Natl Cancer Inst. 2012;104(12):923–30. doi: 10.1093/jnci/djs225 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Wilcox AJ, Weinberg CR, Basso O. On the pitfalls of adjusting for gestational age at birth. Am J Epidemiol. 2011;174(9):1062–8. doi: 10.1093/aje/kwr230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Bjørge T, Sørensen HT, Grotmol T, Engeland A, Stephansson O, Gissler M, et al. Fetal growth and childhood cancer: a population-based study. Pediatrics. 2013;132(5):e1265-75. doi: 10.1542/peds.2013-1317 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Heck JE, Lee P-C, Wu C-K, Tsai H-Y, Ritz B, Arah OA, et al. Gestational risk factors and childhood cancers: a cohort study in Taiwan. Int J Cancer. 2020;147(5):1343–53. doi: 10.1002/ijc.32905 [DOI] [PubMed] [Google Scholar]
  • 33.Hoang TT, Schraw JM, Peckham‐Gregory EC, Scheurer ME, Lupo PJ. Fetal growth and pediatric cancer: a pan‐cancer analysis in 7000 cases and 37 000 controls. Int J Cancer [Internet]. 2024;154(1):41–52. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ijc.34683 [DOI] [PubMed] [Google Scholar]
  • 34.Kessous R, Sheiner E, Landau D, Wainstock T. A history of large for gestational age at birth and future risk for pediatric neoplasms: a population-based cohort study. J Clin Med [Internet]. 2020;9(5):1336. Available from: https://www.mdpi.com/2077-0383/9/5/1336 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Sprehe MR, Barahmani N, Cao Y, Wang T, Forman MR, Bondy M, et al. Comparison of birth weight corrected for gestational age and birth weight alone in prediction of development of childhood leukemia and central nervous system tumors. Pediatr Blood Cancer. 2010;54(2):242–9. doi: 10.1002/pbc.22308 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Kessous R, Sheiner E, Rosen GB, Kapelushnik J, Wainstock T. Increased incidence of childhood lymphoma in children with a history of small for gestational age at birth. Arch Gynecol Obstet [Internet]. 2022;306(5):1485–94. Available from: https://link.springer.com/10.1007/s00404-022-06410-w [DOI] [PubMed] [Google Scholar]
  • 37.Marley AR, Ryder JR, Turcotte LM, Spector LG. Maternal obesity and acute lymphoblastic leukemia risk in offspring: a summary of trends, epidemiological evidence, and possible biological mechanisms. Leuk Res. 2022;121:106924. doi: 10.1016/j.leukres.2022.106924 [DOI] [PubMed] [Google Scholar]
  • 38.Scifres CM. Short- and long-term outcomes associated with large for gestational age birth weight. Obstet Gynecol Clin North Am. 2021;48(2):325–37. doi: 10.1016/j.ogc.2021.02.005 [DOI] [PubMed] [Google Scholar]
  • 39.Connolly GK, Harris RD, Shumate C, Rednam SP, Canfield MA, Plon SE, et al. Pediatric cancer incidence among individuals with overgrowth syndromes and overgrowth features: a population-based assessment in seven million children. Cancer. 2024;130(3):467–75. doi: 10.1002/cncr.35041 [DOI] [PubMed] [Google Scholar]
  • 40.Lupo PJ, Schraw JM, Desrosiers TA, Nembhard WN, Langlois PH, Canfield MA, et al. Association between birth defects and cancer risk among children and adolescents in a population-based assessment of 10 million live births. JAMA Oncol. 2019;5(8):1150. doi: 10.1001/jamaoncol.2019.1215 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Alabdulkarim AO, Alsaeed MI. Prediction of childhood cancer using APGAR score: a systematic review and meta-analysis. Med Sci [Internet]. 2022;26(121):1. Available from: http://discoveryjournals.org/medicalscience/current_issue/v26/n121/ms92e2110.htm [Google Scholar]
  • 42.Bhattacharya S, Beasley M, Pang D, Macfarlane GJ. Maternal and perinatal risk factors for childhood cancer: record linkage study. BMJ Open. 2014;4(1):e003656. doi: 10.1136/bmjopen-2013-003656 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.de Paula Silva N, de Souza Reis R, Garcia Cunha R, Pinto Oliveira JF, Santos M de O, Pombo-de-Oliveira MS. Maternal and birth characteristics and childhood embryonal solid tumors: a population-based report from Brazil. PLoS One [Internet]. 2016;11(10):e0164398. Available from: https://dx.plos.org/10.1371/journal.pone.0164398 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Dixon F, Ziegler DS, Bajuk B, Wright I, Hilder L, Abdel Latif ME, et al. Treatment with nitric oxide in the neonatal intensive care unit is associated with increased risk of childhood cancer. Acta Paediatr. 2018;107(12):2092–8. doi: 10.1111/apa.14436 [DOI] [PubMed] [Google Scholar]
  • 45.Spector LG, Klebanoff MA, Feusner JH, Georgieff MK, Ross JA. Childhood cancer following neonatal oxygen supplementation. J Pediatr [Internet]. 2005;147(1):27–31. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022347605002003 [DOI] [PubMed] [Google Scholar]
  • 46.Jenkinson AC, Kaltsogianni O, Dassios T, Greenough A. Systematic review of the long-term effects of postnatal corticosteroids. J Perinat Med [Internet]. 2023;51(9):1120–8. Available from: https://www.degruyter.com/document/doi/10.1515/jpm-2023-0297/html [DOI] [PubMed] [Google Scholar]
  • 47.Wang J, Guo G, Li A, Cai W-Q, Wang X. Challenges of phototherapy for neonatal hyperbilirubinemia (Review). Exp Ther Med. 2021;21(3):231. doi: 10.3892/etm.2021.9662 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Weinberger B, Laskin DL, Heck DE, Laskin JD. Oxygen toxicity in premature infants. Toxicol Appl Pharmacol. 2002;181(1):60–7. doi: 10.1006/taap.2002.9387 [DOI] [PubMed] [Google Scholar]
  • 49.Naumburg E, Bellocco R, Cnattingius S, Jonzon A, Ekbom A. Supplementary oxygen and risk of childhood lymphatic leukaemia. Acta Paediatr. 2002;91(12):1328–33. doi: 10.1080/08035250216105 [DOI] [PubMed] [Google Scholar]
  • 50.Sarmiento-Salinas FL, Perez-Gonzalez A, Acosta-Casique A, Ix-Ballote A, Diaz A, Treviño S, et al. Reactive oxygen species: role in carcinogenesis, cancer cell signaling and tumor progression. Life Sci. 2021;284:119942. doi: 10.1016/j.lfs.2021.119942 [DOI] [PubMed] [Google Scholar]
  • 51.Contreras ZA, Ritz B, Virk J, Cockburn M, Heck JE. Maternal pre-pregnancy and gestational diabetes, obesity, gestational weight gain, and risk of cancer in young children: a population-based study in California. Cancer Causes Control. 2016;27(10):1273–85. doi: 10.1007/s10552-016-0807-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Kessous R, Wainstock T, Sheiner E. Pre‐pregnancy obesity and childhood malignancies: a population‐based cohort study. Pediatr Blood Cancer [Internet]. 2020;67(6). Available from: https://onlinelibrary.wiley.com/doi/10.1002/pbc.28269 [DOI] [PubMed] [Google Scholar]
  • 53.Stacy SL, Buchanich JM, Ma Z-Q, Mair C, Robertson L, Sharma RK, et al. Maternal obesity, birth size, and risk of childhood cancer development. Am J Epidemiol. 2019;188(8):1503–11. doi: 10.1093/aje/kwz118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Miao J, Chen Y, Liu X, Ye C, Zhou X, Yang Z, et al. Maternal body mass index, gestational weight gain, and risk of cancer in offspring: a systematic review and meta-analysis. Nutrients. 2023;15(7):1601. doi: 10.3390/nu15071601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Petridou ET, Sergentanis TN, Skalkidou A, Antonopoulos CN, Dessypris N, Svensson T, et al. Maternal and birth anthropometric characteristics in relation to the risk of childhood lymphomas. Eur J Cancer Prev. 2015;24(6):535–41. doi: 10.1097/cej.0000000000000122 [DOI] [PubMed] [Google Scholar]
  • 56.Liu X, Chen Q, Tsai H-J, Wang G, Hong X, Zhou Y, et al. Maternal preconception body mass index and offspring cord blood DNA methylation: exploration of early life origins of disease. Environ Mol Mutagen. 2014;55(3):223–30. doi: 10.1002/em.21827 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Sasaki A, Murphy KE, Briollais L, McGowan PO, Matthews SG. DNA methylation profiles in the blood of newborn term infants born to mothers with obesity. Bernard DJ, editor. PLoS One [Internet]. 2022;17(5):e0267946. Available from: https://dx.plos.org/10.1371/journal.pone.0267946 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Soubry A, Murphy SK, Wang F, Huang Z, Vidal AC, Fuemmeler BF. Newborns of obese parents have altered DNA methylation patterns at imprinted genes. Int J Obes [Internet]. 2015;39(4):650–7. Available from: https://www.nature.com/articles/ijo2013193 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Alba-Linares JJ, Pérez RF, Tejedor JR, Bastante-Rodríguez D, Ponce F, Carbonell NG, et al. Maternal obesity and gestational diabetes reprogram the methylome of offspring beyond birth by inducing epigenetic signatures in metabolic and developmental pathways. Cardiovasc Diabetol. 2023;22(1):44. doi: 10.1186/s12933-023-01774-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Bellver J, Mariani G. Impact of parental over- and underweight on the health of offspring. Fertil Steril. 2019;111(6):1054–64. doi: 10.1016/j.fertnstert.2019.02.128 [DOI] [PubMed] [Google Scholar]
  • 61.The National Board of Health and Welfare. Statistics on pregnancies, deliveries and newborn infants 2022. 2023.
  • 62.Angolile CM, Max BL, Mushemba J, Mashauri HL. Global increased cesarean section rates and public health implications: a call to action. Health Sci Rep [Internet]. 2023;6(5). Available from: https://onlinelibrary.wiley.com/doi/10.1002/hsr2.1274 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Jiang L-L, Gao Y-Y, He W-B, Gan T, Shan H-Q, Han X-M. Cesarean section and risk of childhood leukemia: a systematic review and meta-analysis. World J Pediatr. 2020;16(5):471–9. doi: 10.1007/s12519-020-00338-4 [DOI] [PubMed] [Google Scholar]
  • 64.Marcoux S, Soullane S, Lee GE, Auger N. Association between caesarean birth and childhood cancer: An age-lagged approach. Acta Paediatr. 2023;112(2):313–20. doi: 10.1111/apa.16335 [DOI] [PubMed] [Google Scholar]
  • 65.Williams LA, Richardson M, Spector LG, Marcotte EL. Cesarean section is associated with an increased risk of acute lymphoblastic leukemia and hepatoblastoma in children from Minnesota. Cancer Epidemiol Biomarkers Prev. 2021;30(4):736–42. Available from: https://aacrjournals.org/cebp/article/30/4/736/670718/Cesarean-Section-Is-Associated-with-an-Increased [DOI] [PubMed] [Google Scholar]
  • 66.Yang Y, Yu C, Fu R, Xia S, Ni H, He Y, et al. Association of cesarean section with risk of childhood leukemia: a meta‐analysis from an observational study. Hematol Oncol [Internet]. 2023;41(1):182–91. Available from: https://onlinelibrary.wiley.com/doi/10.1002/hon.3070 [DOI] [PubMed] [Google Scholar]
  • 67.Momen NC, Olsen J, Gissler M, Cnattingius S, Li J. Delivery by caesarean section and childhood cancer: a nationwide follow-up study in three countries. BJOG. 2014;121(11):1343–50. doi: 10.1111/1471-0528.12667 [DOI] [PubMed] [Google Scholar]
  • 68.Kampitsi C-E, Mogensen H, Heyman M, Feychting M, Tettamanti G. Mode of delivery and the risk of lymphoblastic leukemia during childhood-A Swedish population-based cohort study. Int J Cancer. 2025;157(10):2041–8. doi: 10.1002/ijc.70027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Mears K, McAuliffe F, Grimes H, Morrison JJ. Fetal cortisol in relation to labour, intrapartum events and mode of delivery. J Obstet Gynaecol. 2004;24(2):129–32. doi: 10.1080/01443610410001645389 [DOI] [PubMed] [Google Scholar]
  • 70.Martinez LD, Glynn LM, Sandman CA, Wing DA, Davis EP. Cesarean delivery and infant cortisol regulation. Psychoneuroendocrinology. 2020;122:104862. doi: 10.1016/j.psyneuen.2020.104862 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Lazar V, Ditu LM, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol. 2018;9. Available from: https://www.frontiersin.org/article/10.3389/fimmu.2018.01830/full [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Wang R, Wiemels JL, Metayer C, Morimoto L, Francis SS, Kadan-Lottick N, et al. Cesarean section and risk of childhood acute lymphoblastic leukemia in a population-based, record-linkage study in California. Am J Epidemiol. 2017;185(2):96–105. doi: 10.1093/aje/kww153 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Contreras ZA, Hansen J, Ritz B, Olsen J, Yu F, Heck JE. Parental age and childhood cancer risk: a Danish population-based registry study. Cancer Epidemiol. 2017;49:202–15. doi: 10.1016/j.canep.2017.06.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Johnson KJ, Carozza SE, Chow EJ, Fox EE, Horel S, McLaughlin CC. Parental age and risk of childhood cancer. Epidemiology [Internet]. 2009;20(4):475–83. Available from: https://journals.lww.com/00001648-200907000-00002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Yip BH, Pawitan Y, Czene K. Parental age and risk of childhood cancers: a population-based cohort study from Sweden. Int J Epidemiol. 2006;35(6):1495–503. doi: 10.1093/ije/dyl177 [DOI] [PubMed] [Google Scholar]
  • 76.Imterat M, Wainstock T, Sheiner E, Kapelushnik J, Fischer L, Walfisch A. Advanced maternal age during pregnancy and the risk for malignant morbidity in the childhood. Eur J Pediatr [Internet]. 2018;177(6):879–86. Available from: http://link.springer.com/10.1007/s00431-018-3136-8 [DOI] [PubMed] [Google Scholar]
  • 77.Politis G, Wagenpfeil S, Welter N, Mergen M, Furtwängler R, Graf N. An observational case-control study on parental age and childhood renal tumors. Cancers (Basel). 2023;15(21):5144. doi: 10.3390/cancers15215144 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Sun Y, Li X, Jiang W, Fan Y, Ouyang Q, Shao W, et al. Advanced paternal age and risk of cancer in offspring. Aging (Albany NY). 2020;13(3):3712–25. doi: 10.18632/aging.202333 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Quetzal Class

14 Oct 2025

Dear Dr. Broberg,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

==============================

Please submit your revised manuscript by Nov 28 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you’re ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the ‘Submissions Needing Revision’ folder to locate your manuscript file.. When you’re ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the ‘Submissions Needing Revision’ folder to locate your manuscript file.. When you’re ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the ‘Submissions Needing Revision’ folder to locate your manuscript file.. When you’re ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the ‘Submissions Needing Revision’ folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled ‘Response to Reviewers’.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled ‘Revised Manuscript with Track Changes’.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled ‘Manuscript’.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols....

We look forward to receiving your revised manuscript.

Kind regards,

Quetzal A. Class, PhD

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.-->--> -->-->Please ensure that your manuscript meets PLOS ONE’s style requirements, including those for file naming. The PLOS ONE style templates can be found at -->-->https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and -->-->https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf-->--> -->-->2. Thank you for stating the following financial disclosure: -->-->a) -->-->-KB,  -->-->-Grant No: Dnr 20 0825 Pj; -->-->-full name: Swedish Cancer Society, -->-->-URL: https://www.cancerfonden.se/om-oss/about-->-->-no-->-->b) -->-->-KB; -->-->-Grant No: PR2020-0012; -->-->-full name: Swedish Childhood Cancer Foundation; -->-->-URL: https://www.barncancerfonden.se;-->-->-no-->-->c) -->-->KB; -->-->-Grant No: 2022-Projekt0162; -->-->-Full name: ALF; -->-->-url: https://www.intramed.lu.se/en/research/alf-funding;-->-->-no-->-->d) -->-->-KB, -->-->-Grant No: 2022-01-11:10, -->-->-full name: Sjöberg Foundation, -->-->-URL: https://sjobergstiftelsen.se/-->-->-no  -->-->Please state what role the funders took in the study.  If the funders had no role, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.” -->-->If this statement is not correct you must amend it as needed. -->-->Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.-->--> -->-->3. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. -->--> -->-->Before we proceed with your manuscript, please address the following prompts:-->--> -->-->a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.-->--> -->-->b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.-->--> -->-->Please update your Data Availability statement in the submission form accordingly.-->--> -->-->4. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.-->--> -->-->5. We note that Figure 1 in your submission contain map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.-->--> -->-->We require you to either present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or remove the figures from your submission:-->--> -->-->a. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license.  -->--> -->-->We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:-->-->“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”-->--> -->-->Please upload the completed Content Permission Form or other proof of granted permissions as an “Other” file with your submission.-->--> -->-->In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”-->--> -->-->b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.-->-->The following resources for replacing copyrighted map figures may be helpful:-->--> -->-->USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/-->-->The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/-->-->Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html-->-->NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/-->-->Landsat: http://landsat.visibleearth.nasa.gov/-->-->USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#-->-->Natural Earth (public domain): http://www.naturalearthdata.com/-->--> -->-->6. Please upload a new copy of Figure 2 as the detail is not clear. Please follow the link for more information:  https://journals.plos.org/plosone/s/figures-->--> -->-->7. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.-->--> -->-->8. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. ?>

Reviewers’ comments:

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

Reviewer #2: No

Reviewer #3: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: Yes

Reviewer #2: No

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

Reviewer #1: The manuscript presents a large-scale population-based case-control study investigating associations between various perinatal factors and childhood cancer risk. The topic is timely, highly relevant, and aligns with PLOS ONE’s focus on scientifically rigorous, ethically conducted research that contributes meaningfully to its field.The manuscript presents a large-scale population-based case-control study investigating associations between various perinatal factors and childhood cancer risk. The topic is timely, highly relevant, and aligns with PLOS ONE’s focus on scientifically rigorous, ethically conducted research that contributes meaningfully to its field.The manuscript presents a large-scale population-based case-control study investigating associations between various perinatal factors and childhood cancer risk. The topic is timely, highly relevant, and aligns with PLOS ONE’s focus on scientifically rigorous, ethically conducted research that contributes meaningfully to its field.The manuscript presents a large-scale population-based case-control study investigating associations between various perinatal factors and childhood cancer risk. The topic is timely, highly relevant, and aligns with PLOS ONE’s focus on scientifically rigorous, ethically conducted research that contributes meaningfully to its field.

Strengths:

The study is based on a well-powered sample (1340 cases, 13,400 controls).

Comprehensive use of Swedish national registries ensures high data reliability.

The use of Cox regression with age as the underlying time scale is a strength over simple logistic regression.

Results are adjusted in a stepwise fashion, providing robustness.

Weaknesses / Suggestions:

Collider bias is acknowledged, and the strategy of multiple models (with/without GA) is commendable. Still, a more detailed justification for the modeling strategy should be included in the Discussion.

Multiple comparisons: The manuscript reports a large number of statistical tests. While correction was intentionally not applied, this choice should be more clearly defended in the limitations section.

Covariate selection: Certain known risk factors (e.g., environmental exposures, family history) are not accounted for. This should be addressed as a limitation.

IVF data: The availability from 1989-2006 and 2007-2021 in separate registries should be more clearly discussed in terms of its impact on data completeness.

Clarity of Writing

Strengths:

The manuscript is overall clearly structured and easy to follow. The English is fluent and mostly well-polished.

Suggestions:

Some paragraphs in the Discussion are overly long and could be made more concise.

Avoid repetition when reporting results, especially when hazard ratios are reiterated in both Results and Discussion.

Minor language edits are needed: Consider proofreading by a native speaker or editor for minor grammatical refinements.

Recommendation: Minor Revision

The manuscript is scientifically sound and of high relevance. The authors should address the following in their revision:

Provide a more explicit discussion on the lack of multiple testing correction.

Briefly elaborate on the implications of the limited IVF data period.

Clarify limitations such as residual confounding and registry-based constraints.

Undertake light English proofreading to enhance polish.

Reviewer #2: In this manuscript the authors have examined the association between several perinatal characteristics and the occurrence of childhood cancer using a register-based case-control data that includes all children diagnosed with cancer in southern Sweden between 1989-2021. The authors found several statistically significant associations: while these associations have been reported in previous studies, results were often conflicting. My main comment to the authors is that I believe that they should have used a conditional logistic regression model to analyze their data instead of a Cox proportional hazards model. See below for more details on this as well as additional comments on the manuscript. In this manuscript the authors have examined the association between several perinatal characteristics and the occurrence of childhood cancer using a register-based case-control data that includes all children diagnosed with cancer in southern Sweden between 1989-2021. The authors found several statistically significant associations: while these associations have been reported in previous studies, results were often conflicting. My main comment to the authors is that I believe that they should have used a conditional logistic regression model to analyze their data instead of a Cox proportional hazards model. See below for more details on this as well as additional comments on the manuscript. In this manuscript the authors have examined the association between several perinatal characteristics and the occurrence of childhood cancer using a register-based case-control data that includes all children diagnosed with cancer in southern Sweden between 1989-2021. The authors found several statistically significant associations: while these associations have been reported in previous studies, results were often conflicting. My main comment to the authors is that I believe that they should have used a conditional logistic regression model to analyze their data instead of a Cox proportional hazards model. See below for more details on this as well as additional comments on the manuscript. In this manuscript the authors have examined the association between several perinatal characteristics and the occurrence of childhood cancer using a register-based case-control data that includes all children diagnosed with cancer in southern Sweden between 1989-2021. The authors found several statistically significant associations: while these associations have been reported in previous studies, results were often conflicting. My main comment to the authors is that I believe that they should have used a conditional logistic regression model to analyze their data instead of a Cox proportional hazards model. See below for more details on this as well as additional comments on the manuscript.

- Abstract: please indicate that the numbers in parentheses represent hazard ratios and 95% confidence intervals.

- Abstract: add to the abstract that the 1340 cancer cases were born in southern Sweden between 1989-2021

- Regarding controls selection, the authors wrote “The inclusion criteria were being born between 1989 and 2021 with no prior history of cancer diagnosis or recorded death before the age of 19 while allowing for cancer diagnosis at the age of 19 or older.” I guess that also controls did not emigrate before age 19, or otherwise you wouldn’t know whether they died or got a cancer diagnosis. However, since the controls cannot die before age 19 and some of the assessed perinatal characteristics are linked to childhood mortality (especially infant mortality) I wonder whether the decision to select controls only among children who didn’t die before age 19 could have led to a slight overestimation of the risk estimates, as these controls likely had more normal perinatal characteristics than the general population (that includes children who died during childhood). Moreover, I think that this sentence should be rephrased since it is not possible to check whether potential controls born in the more recent years are cancer free at age 19 (or have not died by age 19) since they have not reached this age during the study period

- Small for gestational age is defined as a birth weight below the 10th percentile for a specific gestational age, and these percentiles are usually estimated separately for boys and girls. This means that, in the general population, there are approximately 10% of children that are born SGA. However, when defining SGA as SD < -2, there will be a bit more than 2-3% of children defined as being born SGA (in Table 1 the authors reported that it was 4%, which is much lower than the definition of SGA). The same reasoning applies to LGA. Can the authors explain why they have defined SGA/LGA in a different way?

- Information regarding child infections was obtained from the National Patient Register. Why did the authors use only the inpatient register and did not use the outpatient register data (that started in 2001)? Moreover, the authors should write in the text that they use inpatient care data, this is reported only in Table 1

- The authors wrote that “Traditional case-control analyses using logistic regression do not allow estimation of time-varying associations” and therefore used Cox regression models to analyze their matched case-control data. However, I disagree with them because in a case-control study you can assess time varying associations, for example the effect of an exposure on childhood cancer risk during the first five years of life, by restricting the analyses to the cases diagnosed during the age period of interest and their matched controls. It is with time-varying covariates/exposures that one should use Cox regression when analyzing case-control data. I am not an expert on using Cox regression on case-control data but from the study below from Statistics in Medicine it seems that the naïve approach (analyzing the case-control data using the standard Cox regression model as if the data were obtained from a cohort study) could lead to an underestimation of the association. I therefore suggest to the authors to re-run the analyses using a conditional logistic regression model, as all the exposures that they have analyzed (perinatal factors) are not time varying.

Reference: Statistics in Medicine (2003) - Evaluation of Cox’s model and logistic regression for matched case-control data with time-dependent covariates: a simulation study

- The authors wrote “The models were not assessed for characteristics or categories with fewer than ten observations.” Please clarify whether with “ten observations” you mean ten cancer cases for a specific category or if with ten observations you meant a combination of cases and controls

- Why did the authors add a quadratic term for BMI in the regression models? In the main analysis BMI was used as a categorical variable rather than a continuous one

- Did the authors have information regarding genetic syndromes? As these are linked to childhood cancer risk and could also be linked to some perinatal characteristics, is it possible to additionally adjust for genetic syndromes, at least for the most common ones such as Down syndrome, neurofibromatosis type 1, etc.?

- In the discussion the authors wrote “However, several studies, including a large cohort with over 11 thousand cases from Sweden, Denmark and Finland, reported null associations (65,66).”. However, references 65 and 66 refer to studies performed in the UK and the US. Please check that all references are cited correctly.

- I agree with the authors’ decision to not adjust for multiple comparisons. However, the authors should mention in the discussion section that because of the low number of cases and the several associations analyzed, it is possible that some of the reported statistically significant associations could be chance findings.

- In the last paragraph of the discussion, the authors wrote that “Nevertheless, as genetic predisposition explains less than 10% of childhood cancer cases (4), we believe that other perinatal factors, such as environmental factors, could contribute to our findings.” The authors also stated in the conclusion paragraph that “The reported results strongly highlight the significance of the perinatal period as a critical window, particularly for early-onset childhood cancer”. Can the authors report and comment on the proportion of childhood cancer cases that are caused by the exposure assessed in the current study? Moreover, in the abstract the authors wrote “Results indicate several perinatal characteristics associated with the risk of childhood cancer, which is important for prevention”. If the authors believe that these results are important for prevention, this should be thoroughly discussed in the discussion section, together with a discussion on the potential number of cases explained by these exposures and how these results can be used for preventive measures.

Minor comments:

- Check the spelling used throughout the manuscript as sometimes you write leukemia and other times you write leukaemia

- Table 2: Why some ICCC-3 groups are written in italic?

- Table 2: the columns percentages in some instances are not correct and when summed together gave a total > 100%

- Tables should be presented in the text in numerical order. In the text, Table 3 is mentioned before Table 2

- Footnote Table 4: did the authors mean to write inpatient register rather than incoming patient register

- Table 4: why are some numbers underlined in table 4?

Reviewer #3: This is a reasonable study design given the available sample. The major variables of perinatal characteristics, parental education and GA are well formulated as necessary. The variable exclusions for missingness, incompleteness or otherwise made sense.This is a reasonable study design given the available sample. The major variables of perinatal characteristics, parental education and GA are well formulated as necessary. The variable exclusions for missingness, incompleteness or otherwise made sense.This is a reasonable study design given the available sample. The major variables of perinatal characteristics, parental education and GA are well formulated as necessary. The variable exclusions for missingness, incompleteness or otherwise made sense.This is a reasonable study design given the available sample. The major variables of perinatal characteristics, parental education and GA are well formulated as necessary. The variable exclusions for missingness, incompleteness or otherwise made sense.

The statistical analysis section starts on line 165. The investigators give a logical rationale for the approach stating that, ‘Traditional case-control analyses using logistic regression do not allow estimation of time-varying associations. Therefore, in the present study, the Cox proportional hazards regression with child age as the underlying time scale was used to examine the association between perinatal characteristics (Table 1) and risk of childhood cancer.’ Their checking for the appropriateness of proportional hazards was followed appropriately and thus the major model for presenting the results as hazard ratios and their interpretation was reasonable in a somewhat time dependency situation.

However, their explanation of the GA as a potential risk factor of childhood cancer and for most of these characteristics the relationships with GA still remains unclear in this context from the statistical perspective. They note that to investigate GA as a potential risk factor while addressing potential collider bias, they conducted three separate models as outlined. Some detail about the process with actual variable examples would be helpful to the reader.

The Results start on line 207 and series of descriptive tables follow. The tables have so much detail that they are cumbersome to get through especially Tables S1 to S13. There is no discussion of any confounding influences (since adjustments were made as per the investigators), just a summary list of possibly associative characteristics with the outcome. Where there any competing risks in the process?

The limitations are noted on page 17. The investigators note the low numbers in some categories resulting in low power. Was the geographic coverage too small or initial sampling period too narrow. Where does power come into this situation which is a case control study? How relevant is the county of birth in the matching process or is this tied to a genetic or environmental consideration?

**********

what does this mean?). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our Privacy Policy..-->

Reviewer #1: Yes: Nihat Bugra AgaogluNihat Bugra AgaogluNihat Bugra AgaogluNihat Bugra Agaoglu

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link “View Attachments”. If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.. Please note that Supporting Information files do not need this step.. Please note that Supporting Information files do not need this step.. Please note that Supporting Information files do not need this step.

PLoS One. 2026 Apr 16;21(4):e0333752. doi: 10.1371/journal.pone.0333752.r002

Author response to Decision Letter 1


22 Dec 2025

Letter of response

We would like to thank the editor and the reviewers for their time reviewing the manuscript and for their constructive comments and suggestions, which have improved the quality of the manuscript. We have addressed all comments and revised the manuscript accordingly. Our point-by-point responses are given below.

Reviewer #1:

The manuscript presents a large-scale population-based case-control study investigating associations between various perinatal factors and childhood cancer risk. The topic is timely, highly relevant, and aligns with PLOS ONE’s focus on scientifically rigorous, ethically conducted research that contributes meaningfully to its field.

Strengths:The study is based on a well-powered sample (1340 cases, 13,400 controls). Comprehensive use of Swedish national registries ensures high data reliability. The use of Cox regression with age as the underlying time scale is a strength over simple logistic regression. Results are adjusted in a stepwise fashion, providing robustness.

Weaknesses / Suggestions:

-Collider bias is acknowledged, and the strategy of multiple models (with/without GA) is commendable. Still, a more detailed justification for the modelling strategy should be included in the Discussion.

As suggested, we have included the following sentence in the discussion of limitations of the study: “Preterm birth reflects both immaturity and various pathological factors, with currently unclear links to GA. Consequently, in studies on neonatal outcomes, adjusting for GA, as a potential mediator factor, may introduce collider bias (27). In our study, we examined numerous maternal and pregnancy characteristics, including GA, as potential risk factors for childhood cancer, many of which have unclear relationships with GA. To assess GA as both a potential risk factor and a true confounder (e.g. neonatal care, mechanical ventilation therapy) while addressing collider bias, we fitted models both with and without GA, as previously proposed by Wilcox et al., 2011 (27).”

-Multiple comparisons: The manuscript reports a large number of statistical tests. While correction was intentionally not applied, this choice should be more clearly defended in the limitations section.

According to comments and suggestions of reviewers 1 and 2, the following was added to the discussion of limitations of the study: “The statistical analysis includes multiple comparisons, increasing the risk of false positives; however, given the limited statistical power, lowering the significance threshold could potentially overlook biologically meaningful associations. Therefore, we chose to interpret the results cautiously in the context of existing literature rather than adjust for multiple comparisons, still acknowledging that some statistically significant associations may be due to chance. “

-Covariate selection: Certain known risk factors (e.g., environmental exposures, family history) are not accounted for. This should be addressed as a limitation.

This information is included in the conclusion: “Moreover, missing data for some characteristics (e.g., BMI), as well as lack of information on risk factors such as family history and environmental exposures, might represent bias in the current study.”

-IVF data: The availability from 1989-2006 and 2007-2021 in separate registries should be more clearly discussed in terms of its impact on data completeness.

In this study, we have investigated whether assisted pregnancy with IVF (yes vs. no) was associated with the risk of childhood cancer. The Swedish National Quality Register of Assisted Reproduction (Q-IVF) was initiated in 2007; however, for the study period preceding the year of 2007, we could access the same information from the National Medical Birth Register for all study participants. As such, the inclusion of two separate registries to obtain this information did not impact the completeness of our data (i.e. information is available for the whole study population; see Table 2).

Clarity of Writing

Strengths:The manuscript is overall clearly structured and easy to follow. The English is fluent and mostly well-polished.

Suggestions:

-Some paragraphs in the Discussion are overly long and could be made more concise.

As suggested, we have made several discussion paragraphs more concise.

-Avoid repetition when reporting results, especially when hazard ratios are reiterated in both Results and Discussion.

We have removed the repetitions of the results within the discussion.

-Minor language edits are needed: Consider proofreading by a native speaker or editor for minor grammatical refinements.

As suggested, the manuscript was proofread by a native speaker.

Reviewer #2: In this manuscript the authors have examined the association between several perinatal characteristics and the occurrence of childhood cancer using a register-based case-control data that includes all children diagnosed with cancer in southern Sweden between 1989-2021. The authors found several statistically significant associations: while these associations have been reported in previous studies, results were often conflicting. My main comment to the authors is that I believe that they should have used a conditional logistic regression model to analyze their data instead of a Cox proportional hazards model. See below for more details on this as well as additional comments on the manuscript.

- Abstract: please indicate that the numbers in parentheses represent hazard ratios and 95% confidence intervals.

As suggested, we have added HR, 95CI% into all parentheses.

- Abstract: add to the abstract that the 1340 cancer cases were born in southern Sweden between 1989-2021

Revised as suggested.

- Regarding controls selection, the authors wrote “The inclusion criteria were being born between 1989 and 2021 with no prior history of cancer diagnosis or recorded death before the age of 19, while allowing for cancer diagnosis at the age of 19 or older.” I guess that also controls did not emigrate before age 19, or otherwise you wouldn’t know whether they died or got a cancer diagnosis. However, since the controls cannot die before age 19 and some of the assessed perinatal characteristics are linked to childhood mortality (especially infant mortality) I wonder whether the decision to select controls only among children who didn’t die before age 19 could have led to a slight overestimation of the risk estimates, as these controls likely had more normal perinatal characteristics than the general population (that includes children who died during childhood). Moreover, I think that this sentence should be rephrased since it is not possible to check whether potential controls born in the more recent years are cancer-free at age 19 (or have not died by age 19) since they have not reached this age during the study period

According to the reviewer`s comment this part was rephrased as follows: “The inclusion criteria were being born between 1989 and 2021 with no known cancer diagnosis or recorded death before the age of 19, emigration or end of the study, while allowing for cancer diagnosis at the age of 19 or older. “

- Small for gestational age is defined as a birth weight below the 10th percentile for a specific gestational age, and these percentiles are usually estimated separately for boys and girls. This means that, in the general population, there are approximately 10% of children that are born SGA. However, when defining SGA as SD < -2, there will be a bit more than 2-3% of children defined as being born SGA (in Table 1 the authors reported that it was 4%, which is much lower than the definition of SGA). The same reasoning applies to LGA. Can the authors explain why they have defined SGA/LGA in a different way?

There are different definitions of SGA/LGA in the literature. We have used the definition that is mostly used in Sweden. This is based on ultrasonic estimates of foetal weight in normal pregnancies [Marsál K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr. 1996 Jul;85(7):843-8. doi: 10.1111/j.1651-2227.1996.tb14164.x. PMID: 8819552]. Using percentiles by gestational age and sex instead will systematically underestimate the magnitude of the growth restriction in infants born preterm. Another issue is which cut-off to use to define growth restriction. We could have used z-score <-1.28 (equivalent to the 10th percentile), but then a great proportion of the children below the cutoff would have been classified as SGA even if they are just normal but small. Using a more strict cut-off (-1.96) we are more likely to detect growth-restricted children.

- Information regarding child infections was obtained from the National Patient Register. Why did the authors use only the inpatient register and did not use the outpatient register data (that started in 2001)? Moreover, the authors should write in the text that they use inpatient care data, this is reported only in Table 1.

As stated within the methods under section Perinatal characteristics: “ … any child infection requiring specialist in-patient care since birth until the age of one year (yes, no)…”, we limited our analysis to infections recorded in in-patient care registries, as these reflect clinically significant cases requiring hospitalization and are more reliably diagnosed and documented. In contrast, outpatient data were not consistently available throughout the study period.

- The authors wrote that “Traditional case-control analyses using logistic regression do not allow estimation of time-varying associations” and therefore used Cox regression models to analyze their matched case-control data. However, I disagree with them because in a case-control study you can assess time varying associations, for example the effect of an exposure on childhood cancer risk during the first five years of life, by restricting the analyses to the cases diagnosed during the age period of interest and their matched controls. It is with time-varying covariates/exposures that one should use Cox regression when analyzing case-control data. I am not an expert on using Cox regression on case-control data but from the study below from Statistics in Medicine it seems that the naïve approach (analyzing the case-control data using the standard Cox regression model as if the data were obtained from a cohort study) could lead to an underestimation of the association. I therefore suggest to the authors to re-run the analyses using a conditional logistic regression model, as all the exposures that they have analyzed (perinatal factors) are not time varying.

Reference: Statistics in Medicine (2003) - Evaluation of Cox’s model and logistic regression for matched case-control data with time-dependent covariates: a simulation study

We thank the reviewer for this comment. We are aware that traditionally in case–control settings with matched controls and time-fixed exposures, conditional logistic regression is commonly applied. Cox regression falls under statistical techniques aimed at analysing “time-to-event” data and/or assessing the relationship between a given exposure and the occurrence of an outcome after a follow-up period among a cohort of individuals (ElHafeez et al., 2021; 10.1155/2021/1302811). In the present study, follow-up lengths, or time-to-event, vary considerably, with children born in the later part of the study period having significantly shorter follow-up compared to those born in the early years of the study. As such we wanted to address age at diagnosis (follow-up) as a potential factor influencing our tested association. While we agree that such patterns can also be explored through stratified logistic regression (restricting to cases diagnosed within specific age windows), such approaches require arbitrary partitioning of time and substantially reduce statistical power. In contrast, the Cox model allows us to use the full temporal information.

With the design of the present study, using loose matching (year of birth, county of birth and sex only), we don’t think that a matched analysis would be appropriate. In a simulation study, Kuo et al conclude: “Unmatched methods, e.g., unconditional logistic regression, are viable options for loose-matching data based on our findings. When the study design involves other complex features such as censoring and repeated measures, matching on a few demographic variables can be ignored if the confounding effect is not very large. Standard methods such as Cox regression and generalised estimating equation then can be readily applied.” [Kuo CL, Duan Y, Grady J. Unconditional or Conditional Logistic Regression Model for Age-Matched Case-Control Data? Front Public Health. 2018 Mar 2;6:57. doi: 10.3389/fpubh.2018.00057. PMID: 29552553; PMCID: PMC5840200].

Based on the comments from the other two reviewers, who supported our choice of statistical analyses—one specifically highlighting the use of Cox regression as a strength of the study—we have decided to retain Cox regression in the present study, unless the editor advises otherwise.

- The authors wrote “The models were not assessed for characteristics or categories with fewer than ten observations.” Please clarify whether with “ten observations” you mean ten cancer cases for a specific category or if with ten observations you meant a combination of cases and controls

We have rephrased the sentence as follows: “The models were not assessed for characteristics or categories when there were fewer than ten observations in a group of cases or controls.”

- Why did the authors add a quadratic term for BMI in the regression models? In the main analysis BMI was used as a categorical variable rather than a continuous one

Inclusion of the quadratic term of BMI was run as a sensitivity analysis; this was omitted from the manuscript.

- Did the authors have information regarding genetic syndromes? As these are linked to childhood cancer risk and could also be linked to some perinatal characteristics, is it possible to additionally adjust for genetic syndromes, at least for the most common ones such as Down syndrome, neurofibromatosis type 1, etc.?

We additionally obtained data on the diagnosis of some cancer predisposing syndromes, including Down syndrome, Neurofibromatosis type 1, Congenital malformation syndromes involving early overgrowth, and Von Hippel-Lindau syndrome. We conducted further analyses assessing the association between the diagnosis of these syndromes (yes/no) and the risk of childhood cancer. As suggested, we also performed a sensitivity analysis evaluating the association of all studied perinatal characteristics after excluding children diagnosed with any of these syndromes (n = 49). The exclusion of those children did not significantly affect our findings. These analyses are now added into the supplementary materials and described within the methods, results and discussion part of the manuscript.

- In the discussion the authors wrote “However, several studies, including a large cohort with over 11 thousand cases from Sweden, Denmark and Finland, reported null associations (65,66).”. However, references 65 and 66 refer to studies performed in the UK and the US. Please check that all references are cited correctly.

We have corrected the citation order of the references.

- I agree with the authors’ decision to not adjust for multiple comparisons. However, the authors should mention in the discussion section that because of the low number of cases and the several associations analyzed, it is possible that some of the reported statistically significant associations could be chance findings.

According to the comments and suggestions of 2 reviewers (reviewer 1 and 2), the following was added into the discussion of the manuscript within the limitations of the study part: “The statistical analysis of this study includes multiple comparisons, increasing the risk of false positives; however, given the limited statistical power, lowering the significance threshold could potentially overlook meaningful associations. Therefore, we chose to interpret the results cautiously in the context of existing literature rather than adjust for multiple comparisons, acknowle

Attachment

Submitted filename: Response to reviewers.docx

pone.0333752.s017.docx (30.9KB, docx)

Decision Letter 1

Melvin Marzan

16 Mar 2026

<p>Parental, pregnancy and neonatal characteristics during the perinatal period as potential risk factors for childhood cancer: FeToxCancer case-control study

PONE-D-25-24435R1

Dear Dr. Broberg,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information’ link at the top of the page. For questions related to billing, please contact  and clicking the ‘Update My Information’ link at the top of the page. For questions related to billing, please contact  and clicking the ‘Update My Information’ link at the top of the page. For questions related to billing, please contact  and clicking the ‘Update My Information’ link at the top of the page. For questions related to billing, please contact billing support....

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Melvin Marzan, BSc, MSc TM, PhD

Academic Editor

PLOS One

Additional Editor Comments (optional):

Reviewers’ comments:

Reviewer’s Responses to Questions

Comments to the Author

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #2: No

Reviewer #3: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

Reviewer #2: The authors have sufficiently addressed all my previous comments.

Reviewer #3: (No Response)

**********

what does this mean?). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our Privacy Policy..-->

Reviewer #2: No

Reviewer #3: No

**********

Acceptance letter

Melvin Marzan

PONE-D-25-24435R1

PLOS One

Dear Dr. Broberg,

I’m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they’ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Melvin Marzan

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Distribution of studied perinatal characteristics between cases of leukaemia, CNS tumours, lymphoma and other cancer types combined and matching controls.

    (DOCX)

    pone.0333752.s001.docx (36.2KB, docx)
    S2 Table. Associations of perinatal characteristics with leukaemia.

    (DOCX)

    pone.0333752.s002.docx (34.5KB, docx)
    S3 Table. Associations of perinatal characteristics with CNS tumours.

    (DOCX)

    pone.0333752.s003.docx (34.8KB, docx)
    S4 Table. Associations of perinatal characteristics with lymphoma.

    (DOCX)

    pone.0333752.s004.docx (34.5KB, docx)
    S5 Table. Associations of perinatal characteristics with other cancer types combined (ICCC groups IV to XII including by ICCC unclassified).

    (DOCX)

    pone.0333752.s005.docx (34.4KB, docx)
    S6 Table. Associations of perinatal characteristics with risk of childhood cancer and cancer types after exclusion of children diagnosed with cancer-predisposing syndromes#.

    (DOCX)

    pone.0333752.s006.docx (38.2KB, docx)
    S7 Table. Association of birthweight for GA with risk of overall childhood cancer and leukaemia after additional adjustment for gestational diabetes.

    (DOCX)

    pone.0333752.s007.docx (22.7KB, docx)
    S8 Table. Association of 5-min Apgar with other cancer types combined after additional adjustment for birthweight for GA and neonatal care (a) and distribution of 5-min Apgar according to the age at diagnosis (b).

    (DOCX)

    pone.0333752.s008.docx (23.7KB, docx)
    S9 Table. Distribution and association of specific neonatal therapies with overall childhood cancer (a), and association of mechanical ventilation with other cancer types (b).

    (DOCX)

    pone.0333752.s009.docx (29.1KB, docx)
    S10 Table. Association of maternal BMI with leukemia, CNS tumor and lymphoma after additional adjustment for birthweight for GA (a) or gestational diabetes (b).

    (DOCX)

    pone.0333752.s010.docx (23.6KB, docx)
    S11 Table. Association between mode of delivery and risk of other cancer types combined after additional adjustment for birthweight for GA and 5-min Apgar score.

    (DOCX)

    pone.0333752.s011.docx (24.3KB, docx)
    S12 Table. Association between parental 5-year advance in age with risk of childhood cancer and specific cancer types.

    (DOCX)

    pone.0333752.s012.docx (23.2KB, docx)
    S13 Table. Distribution and associations of additionally tested perinatal characteristics with childhood cancer.

    (DOCX)

    pone.0333752.s013.docx (28.8KB, docx)
    S14 Table. Associations of birthweight for GA with maternal BMI and Gestational diabetes (a) and of 5-min Apgar with birthweight for GA, gestational age and admission to neonatal care (b).

    (DOCX)

    pone.0333752.s014.docx (24.3KB, docx)
    S1 Fig. Forest plot presenting associations of birthweight for GA, 5-min Apgar score, admission to neonatal care, mechanical ventilation treatment, and mode of delivery with the risk of overall childhood cancer, leukaemia or other cancer types combined after the exclusion of cancer cases diagnosed at birth (adjusted according to model 3; ** p < 0.01, *p < 0.05; other types combined– ICCC groups IV-XII including unclassified diagnoses; AGA – adequate for GA, SGA–small for GA, LGA–large for GA).

    (DOCX)

    pone.0333752.s015.docx (275.2KB, docx)
    Attachment

    Submitted filename: Response to reviewers.docx

    pone.0333752.s017.docx (30.9KB, docx)

    Data Availability Statement

    Due to the personal data collected and potentially identifying information l contained within the data, the data are available upon request. Ethical approval by the Swedish Ethical Review Authority may be necessary, and requests for data may be sent to: SOCIALSTYRELSEN Statistikavdelningen Enheten för Mikrodata 106 30 Stockholm email: socialstyrelsen@socialstyrelsen.se.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES